<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia - Kwan, J - 2022 | Cochrane Library</title> <meta content="Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia - Kwan, J - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012269.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia - Kwan, J - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012269.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012269.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia" name="citation_title"/> <meta content="Joseph Kwan" name="citation_author"/> <meta content="Imperial College London" name="citation_author_institution"/> <meta content="joseph.kwan@nhs.net" name="citation_author_email"/> <meta content="Melanie Hafdi" name="citation_author"/> <meta content="Amsterdam UMC, University of Amsterdam" name="citation_author_institution"/> <meta content="Lorraine L W Chiang" name="citation_author"/> <meta content="The University of Hong Kong, Queen Mary Hospital" name="citation_author_institution"/> <meta content="Phyo K Myint" name="citation_author"/> <meta content="University of Aberdeen" name="citation_author_institution"/> <meta content="Li Siang Wong" name="citation_author"/> <meta content="University of Glasgow" name="citation_author_institution"/> <meta content="Terry J Quinn" name="citation_author"/> <meta content="University of Glasgow" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD012269.pub2" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/07/13" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012269.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012269.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012269.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Aspirin [therapeutic use]; *Cerebral Small Vessel Diseases [complications, diagnostic imaging, drug therapy]; *Cognitive Dysfunction [drug therapy, prevention &amp; control]; *Dementia [prevention &amp; control]; Neuroimaging; Platelet Aggregation Inhibitors [therapeutic use]; *Stroke [diagnostic imaging, drug therapy, prevention &amp; control]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012269.pub2&amp;doi=10.1002/14651858.CD012269.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012269.pub2&amp;doi=10.1002/14651858.CD012269.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012269.pub2&amp;doi=10.1002/14651858.CD012269.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012269.pub2&amp;doi=10.1002/14651858.CD012269.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012269.pub2&amp;doi=10.1002/14651858.CD012269.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012269.pub2&amp;doi=10.1002/14651858.CD012269.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012269.pub2&amp;doi=10.1002/14651858.CD012269.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012269.pub2&amp;doi=10.1002/14651858.CD012269.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012269.pub2&amp;doi=10.1002/14651858.CD012269.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012269.pub2&amp;doi=10.1002/14651858.CD012269.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012269.pub2&amp;doi=10.1002/14651858.CD012269.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012269.pub2&amp;doi=10.1002/14651858.CD012269.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012269.pub2&amp;doi=10.1002/14651858.CD012269.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012269.pub2&amp;doi=10.1002/14651858.CD012269.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012269.pub2&amp;doi=10.1002/14651858.CD012269.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012269.pub2&amp;doi=10.1002/14651858.CD012269.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012269.pub2&amp;doi=10.1002/14651858.CD012269.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012269.pub2&amp;doi=10.1002/14651858.CD012269.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012269.pub2&amp;doi=10.1002/14651858.CD012269.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012269.pub2&amp;doi=10.1002/14651858.CD012269.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012269.pub2&amp;doi=10.1002/14651858.CD012269.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012269.pub2&amp;doi=10.1002/14651858.CD012269.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012269.pub2&amp;doi=10.1002/14651858.CD012269.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="BqmVIxTs";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012269\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012269\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012269\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012269\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","ms","ja","fa","pl","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012269.pub2",title:"Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia",firstPublishedDate:"Jul 13, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Dementia and Cognitive Improvement Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=BqmVIxTs&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012269.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012269.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012269.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012269.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012269.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012269.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012269.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012269.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012269.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012269.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012269.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012269.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012269.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012269.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5117 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012269.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012269.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012269.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012269.pub2/full#CD012269-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012269.pub2/full#CD012269-sec-0074"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012269.pub2/full#CD012269-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012269.pub2/full#CD012269-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012269.pub2/full#CD012269-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012269.pub2/full#CD012269-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012269.pub2/full#CD012269-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012269.pub2/full#CD012269-sec-0065"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012269.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012269.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012269.pub2/appendices#CD012269-sec-0078"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012269.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012269.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012269.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012269.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012269.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012269.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012269.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012269.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012269.pub2/information#CD012269-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Joseph Kwan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012269.pub2/information#CD012269-cr-0005">Melanie Hafdi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012269.pub2/information#CD012269-cr-0006">Lorraine L W Chiang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012269.pub2/information#CD012269-cr-0007">Phyo K Myint</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012269.pub2/information#CD012269-cr-0008">Li Siang Wong</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012269.pub2/information#CD012269-cr-0009">Terry J Quinn</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012269.pub2/information/en#CD012269-sec-0083">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 13 July 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012269.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012269.pub2">https://doi.org/10.1002/14651858.CD012269.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012269-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012269-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012269-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012269-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012269-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012269-abs-0011">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012269-abs-0001" lang="en"> <section id="CD012269-sec-0001"> <h3 class="title" id="CD012269-sec-0001">Background</h3> <p>Cerebral small vessel disease is a progressive disease of the brain's deep perforating blood vessels. It is usually diagnosed based on lesions seen on brain imaging. Cerebral small vessel disease is a common cause of stroke but can also cause a progressive cognitive decline. As antithrombotic therapy is an established treatment for stroke prevention, we sought to determine whether antithrombotic therapy might also be effective in preventing cognitive decline in people with small vessel disease. </p> </section> <section id="CD012269-sec-0002"> <h3 class="title" id="CD012269-sec-0002">Objectives</h3> <p>To assess the effects of antithrombotic therapy for prevention of cognitive decline in people with small vessel disease on neuroimaging but without dementia. </p> </section> <section id="CD012269-sec-0003"> <h3 class="title" id="CD012269-sec-0003">Search methods</h3> <p>We searched ALOIS, the Cochrane Dementia and Cognitive Improvement Review Group's Specialised Register, and the Cochrane Stroke Group's Specialised Register; the most recent search was on 21 July 2021. We also searched MEDLINE, Embase, four other databases and two trials registries. We searched the reference lists of the articles retrieved from these searches. As trials with a stroke focus may include relevant subgroup data, we complemented these searches with a focussed search of all antithrombotic titles in the Cochrane Stroke Group database.  </p> </section> <section id="CD012269-sec-0004"> <h3 class="title" id="CD012269-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCT) of people with neuroimaging evidence of at least mild cerebral small vessel disease (defined here as white matter hyperintensities, lacunes of presumed vascular origin and subcortical infarcts) but with no evidence of dementia. The trials had to compare antithrombotic therapy of minimum 24 weeks' duration to no antithrombotic therapy (either placebo or treatment as usual), or compare different antithrombotic treatment regimens. Antithrombotic therapy could include antiplatelet agents (as monotherapy or combination therapy), anticoagulants or a combination. </p> </section> <section id="CD012269-sec-0005"> <h3 class="title" id="CD012269-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened all the titles identified by the searches. We assessed full texts for eligibility for inclusion according to our prespecified selection criteria, extracted data to a proforma and assessed risk of bias using the Cochrane tool for RCTs. We evaluated the certainty of evidence using GRADE. Due to heterogeneity across included participants, interventions and outcomes of eligible trials, it was not possible to perform meta‐analyses. </p> </section> <section id="CD012269-sec-0006"> <h3 class="title" id="CD012269-sec-0006">Main results</h3> <p>We included three RCTs (3384 participants). One study investigated the effect of antithrombotic therapy in participants not yet on antithrombotic therapy; two studies investigated the effect of additional antithrombotic therapy, one in a population already taking a single antithrombotic agent and one in a mixed population (participants on an antithrombotic drug and antithrombotic‐naive participants). Intervention and follow‐up durations varied from 24 weeks to four years. </p> <p>Jia 2016 was a placebo‐controlled trial assessing 24 weeks of treatment with DL‐3‐n‐butylphthalide (a compound with multimodal actions, including a putative antiplatelet effect) in 280 Chinese participants with vascular cognitive impairment caused by subcortical ischaemic small vessel disease, but without dementia. There was very low‐certainty evidence for a small difference in cognitive test scores favouring treatment with DL‐3‐n‐butylphthalide, as measured by the 12‐item Alzheimer’s Disease Assessment Scale‐Cognitive subscale (adjusted mean difference −1.07, 95% confidence interval (CI) −2.02 to −0.12), but this difference may not be clinically relevant. There was also very low‐certainty evidence for greater proportional improvement measured with the Clinician Interview‐Based Impression of Change‐Plus Caregiver Input (57% with DL‐3‐n‐butylphthalide versus 42% with placebo; P = 0.01), but there was no difference in other measures of cognition (Mini‐Mental State Examination and Clinical Dementia Rating) or function. There was no evidence of a difference in adverse events between treatment groups. </p> <p>The SILENCE RCT compared antithrombotic therapy (aspirin) and placebo during four years of treatment in 83 participants with 'silent brain infarcts' who were on no prior antithrombotic therapy. There was very low‐certainty evidence for no difference between groups across various measures of cognition and function, rates of stroke or adverse events. </p> <p>The Secondary Prevention of Subcortical Stroke Study (SPS3) compared dual antiplatelet therapy (clopidogrel plus aspirin) to aspirin alone in 3020 participants with recent lacunar stroke. There was low‐certainty evidence of no effect on cognitive outcomes as measured by the Cognitive Abilities Screening Instruments (CASI) assessed annually over five years. There was also low‐certainty evidence of no difference in the annual incidence of mild cognitive decline between the two treatment groups (9.7% with dual antiplatelet therapy versus 9.9% with aspirin), or the annual stroke recurrence rate (2.5% with dual antiplatelet therapy versus 2.7% with aspirin). Bleeding risk may be higher with dual antiplatelet therapy (hazard ratio (HR) 2.15, 95% CI 1.49 to 3.11; low certainty evidence), but there may be no significant increase in intracerebral bleeding risk (HR 1.52, 95% CI 0.79 to 2.93; low‐certainty evidence). </p> <p>None of the included trials assessed the incidence of new dementia.</p> </section> <section id="CD012269-sec-0007"> <h3 class="title" id="CD012269-sec-0007">Authors' conclusions</h3> <p>We found no convincing evidence to suggest any clinically relevant cognitive benefit of using antithrombotic therapy in addition to standard treatment in people with cerebral small vessel disease but without dementia, but there may be an increased bleeding risk with this approach. There was marked heterogeneity across the trials and the certainty of the evidence was generally poor. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012269-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012269-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012269-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012269-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012269-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012269-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD012269-abs-0007">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012269-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD012269-abs-0010">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012269-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012269-abs-0002" lang="en"> <h3>Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia </h3> <p><b>Background</b> </p> <p>Disruption of blood flow to the brain can cause problems with memory and thinking. In the condition called 'cerebral small vessel disease', there is damage to the smallest blood vessels that run deep in the brain. This damage can cause stroke but can also be seen on brain scans in people with no obvious stroke symptoms. Cerebral small vessel disease usually gets worse over time, and in some people can cause a decline in memory and thinking. If this decline gets severe enough to affect a person's ability to manage their daily activities independently, then it is described as a type of vascular dementia. We know that blood‐thinning medications such as aspirin can prevent stroke. We wanted to know whether blood‐thinning medications might also prevent the decline in memory and thinking that is seen in cerebral small vessel disease. </p> <p><b>Review question</b>  </p> <p>Are blood‐thinning medications effective and safe in preventing the decline in memory and thinking in people with cerebral small vessel disease? </p> <p><b>What we did </b> </p> <p>We searched the medical literature up to 21 July 2021 looking for studies that compared blood‐thinning medications given over at least 24 weeks to a comparator, which could have been either usual care or a placebo (dummy) tablet. To make the comparison fair, the studies had to assign people randomly to blood‐thinning medications or the comparator treatment. We were interested in the effects on participants' performance in memory and thinking tests, their ability to look after themselves, their risk of developing dementia and stroke, and side effects (especially from bleeding). Because the studies were so different from each other in terms of the type of participants, medications and assessments, we were unable to combine the results in analyses. Rather, we described the results of individual studies and assessed how confident we were in their findings. </p> <p><b>What we found</b>  </p> <p>We included three studies with 3384 participants. These studies were very different in terms of the participants (some with and some without stroke), the medications studied (single and combinations of different blood‐thinners), and how the effects on memory and thinking were measured (different tests used for assessment). No trial consistently demonstrated an improvement in performance in memory and thinking tests or in daily activities. No trial assessed for a new diagnosis of dementia. There was suggestion of blood‐thinning medications possibly causing an increased risk of bleeding, including gastrointestinal bleeding, but the numbers were too small to be certain that this was not just a chance difference. Overall, we considered that the quality of the evidence was poor for answering our review question regarding memory and thinking. Much of the information we needed was not reported. Two of the three studies were small, meaning that there was uncertainty around their results. In the only study that reported any benefit from blood‐thinning medication, different measures of memory and thinking did not all agree with each other. Lastly, where there was an improvement in memory and thinking, the size of this improvement may have been too small to make a noticeable difference to the individual in reality. </p> <p><b>Conclusions </b> </p> <p>We found no convincing evidence that taking blood‐thinning medications is beneficial for memory and thinking in people with cerebral small vessel disease. However, the studies were very different from each other, and each one had limitations with regard to our review question. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012269-sec-0074" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012269-sec-0074"></div> <h3 class="title" id="CD012269-sec-0075">Implications for practice</h3> <section id="CD012269-sec-0075"> <p>There is insufficient evidence to support the routine use of antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia. We identified only three studies reporting on our research question and their results were inconclusive. The overall evidence reported in this review was of very low to low certainty,  meaning  our confidence in the reported effect estimates is limited.  </p> <p>In this review, we considered cerebral small vessel disease (cSVD) as a single condition, but under this rubric is a spectrum of severity of neuroimaging and phenotypic features and people living with cSVD may have other potential indications for antithrombotics. At the individual patient level, a degree of risk stratification is required around antithrombotic prescription. Recommendations on antithrombotic therapy in practice cannot be made based on the findings of this review, as the studies were too heterogeneous in terms of populations (including both acute and chronic small vessel disease in both naïve and therapeutic populations) and interventions (including single and double antithrombotic therapy). </p> </section> <h3 class="title" id="CD012269-sec-0076">Implications for research</h3> <section id="CD012269-sec-0076"> <p>Our review highlights unanswered questions and aspects of research methods that could be improved for future studies.  </p> <p>The available evidence on adverse effects, particularly bleeding, is a reminder that longer‐term administration of antithrombotics presents risks. Any potential long‐term cognitive or stroke benefit would need to be greater than the bleeding risk. Arguments around using antithrombotic agents that have lesser bleeding risk and may have beneficial effects on other aspects of vascular biology (e.g. cilostazol) are compelling but so far lack convincing clinical trial evidence. </p> <p>While one could argue that large‐scale, long‐term follow‐up RCTs of antithrombotic therapy in cSVD are needed, given the associated bleeding risk and increasing evidence of no cognitive benefit of aspirin primary prevention, these trials may need more sophisticated risk stratification than presence/absence of cSVD change. </p> <p>Novel antithrombotic agents with lower bleeding risk could have potential efficacy and we would support the calls for all future (cerebro) vascular trials to include cognitive outcomes. </p> <p>The focus of our review is on cognition, but the clinical manifestations of cSVD are not restricted to cognitive decline. No cSVD trials assessed other aspects of the cSVD phenotype such as disordered gait, apathy, mood disturbance, continence, etc. It would be useful to find out the clinical features of greatest relevance to people living with cSVD and design trial outcomes around these. </p> <p>Finally, the review process highlighted the difficulty of searching the published literature for studies of cSVD. Greater standardisation of terminology and indexing (as has been achieved for the neuroimaging aspects of cSVD) would aid future evidence synthesis. In the meantime, the development and validation of search syntax for cSVD would be a useful step.  </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012269-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012269-sec-0008"></div> <div class="table" id="CD012269-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antiplatelet drug compared to placebo in mixed populations (with or without pre‐existing antiplatelet therapy) for the prevention of cognitive decline and dementia in people with cerebral small vessel disease and no dementia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Antiplatelet drug compared to placebo, in populations with mixed prevalence of antiplatelet drug use at baseline, for the prevention of cognitive decline and dementia in people with cerebral small vessel disease and no dementia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with cerebral small vessel disease and no dementia either already on antiplatelet therapy or not<br/><b>Setting:</b> outpatient services<br/><b>Intervention:</b> adding antiplatelet therapy in populations where some participants may have been taking antiplatelet <br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Impact</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in cognitive function from baseline</b><br/>assessed with ADAS‐Cog, CIBIC‐plus, MMSE, CDR, CDR‐SB,  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 trial reported a beneficial effect across 2 of 5 cognitive outcomes (ADAS‐Cog and CIBIC‐plus), but the size of benefit may be less than the minimal important clinical difference. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incident dementia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major bleeding (intracranial and extracranial)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 trial reported no difference between treatment groups for this outcome.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Functional ability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 trial reported no difference in functional anility between treatment groups</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stroke or transient ischaemic attack</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 trial reported no difference in stroke or transient ischaemic attacks between treatment groups </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any adverse events (excluding major bleeding)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 study reported no difference in adverse events between treatment groups</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal from study medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 trial reported an increase in medication withdrawal in those taking additional antiplatelets in comparison to those taking a placebo (OR for withdrawal from treatment 1.88, 95% CI 0.90 to 3.42) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ADAS‐Cog:</b> Alzheimer's Disease Assessment Scale – Cognitive Subscale; <b>ADL:</b> activities of daily living; <b>CDR‐SB:</b> Clinical Dementia Rating scale Sum of Boxes;<b> CI:</b> confidence interval; <b>MMSE:</b> Mini‐Mental State Examination; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level because all participants had cognitive impairment at baseline, making it difficult to translate these findings to the general small‐vessel disease population.<br/><sup>b</sup>Downgraded one level as it is arguable whether DL‐3‐n‐butylphthalide should technically be classified as an antithrombotic therapy.<br/><sup>c</sup>Downgraded one level for imprecision as only one study contributed to this finding. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012269-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Antiplatelet therapy compared to placebo for prevention of cognitive decline and dementia in people with cerebral small vessel disease and no dementia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Antiplatelet therapy compared to placebo in antiplatelet naive populations for prevention of cognitive decline and dementia in people with cerebral small vessel disease and no dementia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with cerebral small vessel disease and no dementia not on antiplatelet therapy<br/><b>Setting: </b> outpatient services<br/><b>Intervention:</b> antiplatelet therapy<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Impact</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in cognitive function from baseline</b><br/>assessed with: NPB,  MMSE </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 trial reported no difference between treatment groups.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incident dementia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major bleeding (intracranial and extracranial)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Functional ability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 trial reported no difference in activities of daily living between treatment groups.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stroke or transient ischaemic attack</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 trial reported no difference between treatment groups.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any adverse events (excluding major bleeding)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 trial reported no difference between treatment groups.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal from study medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 trial reported slightly more dropout in the intervention group (33.3%) than in the placebo group (19.2%) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>MMSE:</b> Mini‐Mental State Examination; <b>NPB:</b> Neuropsychological test Battery; <b>RCT:</b> randomised controlled trial.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level as there was no (clear) statement whether participants with dementia were actively excluded.<br/><sup>b</sup>Downgraded one level due to serious risk of bias in included studies.<br/><sup>c</sup>Downgraded one level due to imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012269-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Dual antiplatelet therapy compared to single antiplatelet therapy for prevention of cognitive decline and dementia in people with cerebral small vessel disease and no dementia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Dual antiplatelet therapy compared to single antiplatelet therapy for prevention of cognitive decline and dementia in people with cerebral small vessel disease and no dementia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with cerebral small vessel disease and no dementia<br/><b>Setting:</b> outpatient services<br/><b>Intervention:</b> dual antiplatelet therapy<br/><b>Comparison:</b> single antiplatelet therapy </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Impact</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in cognitive function from baseline</b><br/>assessed with CASI score </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 trial reported no beneficial effect of additional antiplatelet treatment over placebo on cognitive functioning assessed with the CASI score. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3020<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incident dementia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No trials reported this outcome</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major bleeding (intracranial and extracranial)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 trial reported a difference in major haemorrhagic events (105/1517 participants with intervention vs 56/1503 participants with control; HR 1.97, 95% CI 1.41 to 2.71) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3020<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Functional ability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No trials reported this outcome.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stroke or transient ischaemic attack</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 trial reported there was probably no effect of additional antiplatelet treatment on stroke or TIA </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3020<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any adverse events (excluding major bleeding)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No trials reported this outcome.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal from study medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 trial reported an increase in medication withdrawal in those taking additional antiplatelets in comparison to those taking a placebo (30% with intervention vs 27% with control; P = 0.02). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3020<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CASI:</b> Cognitive Abilities Screening Instrument; <b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>RCT:</b> randomised controlled trial.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for imprecision as only one study contributed to this finding.<br/><sup>b</sup>Downgraded one level for indirectness because most participants had mild cognitive impairment at baseline, making it difficult to translate these findings to the general small‐vessel disease population. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012269-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012269-sec-0009"></div> <section id="CD012269-sec-0010"> <h3 class="title" id="CD012269-sec-0010">Description of the condition</h3> <p>Dementia is a progressive condition in which acquired cognitive impairment is severe enough to affect a person's ability to manage everyday activities. Usually it occurs in later life and is caused by neurodegenerative conditions, of which the most common are Alzheimer's disease and cerebrovascular disease. Dementia is an international public health concern, affecting 35 million people worldwide (<a href="./references#CD012269-bbs2-0055" title="PrinceM , BryceR , AlbaneseE , WimoA , RibeiroW , FerriCP . The global prevalence of dementia: a systematic review and meta-analysis. Alzheimer's &amp; Dementia2013;9:63-75.e2. [DOI: 10.1016/j.jalz.2012.11.007]">Prince 2013</a>), with a global annual cost of over USD 600 billion (<a href="./references#CD012269-bbs2-0064" title="WimoA , JönssonL , BondJ , PrinceM , WinbladB , Alzheimer Disease International. The worldwide economic impact of dementia 2010. Alzheimers Dementia2013;9:1-11.e3. [DOI: 10.1016/j.jalz.2012.11.006]">Wimo 2013</a>). By 2050, it is estimated that the impact of dementia will exceed that of heart disease, cancer and stroke combined (<a href="./references#CD012269-bbs2-0066" title="PrinceM , WimoA , GuerchetM , AliGC , WuYT , PrinaM . World Alzheimer Report 2015. London (UK): Alzheimer's Disease International (ADI), 2015.">World Alzheimer Report 2015</a>). Currently, approved pharmacological treatments for dementia offer symptomatic benefit (<a href="./references#CD012269-bbs2-0028" title="BattleCE , Abdul-RahimnAH , ShenkinSD , HewittJ , QuinnTJ . Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis. Cochrane Database of Systematic Reviews2021, Issue 2. Art. No: CD013306. [DOI: 10.1002/14651858.CD013306.pub2]">Battle 2021</a>; <a href="./references#CD012269-bbs2-0049" title="McShaneR , WestbyMJ , RobertsE , MinakaranN , SchneiderL , FarrimondL , et al. Memantine for dementia. Cochrane Database of Systematic Reviews2019, Issue 3. Art. No: CD003154. [DOI: 10.1002/14651858.CD003154.pub6]">McShane 2019</a>), but there is no proven drug intervention to prevent or reduce cognitive decline. </p> <p>Cerebral small vessel disease (cSVD) is a dynamic, whole brain syndrome thought to result from pathology in the arterioles, capillaries and venules of the brain. cSVD may be an asymptomatic finding on neuroimaging or may present with a range of clinical manifestations, including clinical stroke, gait impairments, neuropsychiatric problems and frank dementia. The overall prevalence of asymptomatic small vessel ischaemia seen on brain imaging is high, up to 67% of older adults in one community‐based study (<a href="./references#CD012269-bbs2-0034" title="Del BruttoOH , MeraRM , ZambranoM , LamaJ , Del BruttoVJ , CastilloPR . Poor sleep quality and silent markers of cerebral small vessel disease: a population-based study in community-dwelling older adults (the Atahualpa Project). Sleep Medicine2015;16:428-31. [DOI: 10.1016/j.sleep.2014.10.023]">Del Brutto 2015</a>). As cSVD is associated with hypertension, diabetes and other vascular risk factors, treatment of cSVD has tended to focus on modifying vascular risk (<a href="./references#CD012269-bbs2-0062" title="WardlawJM , SmithC , DichgansM . Small vessel disease: mechanisms and clinical implications. Lancet Neurology2019;18:684-96. [DOI: 10.1016/S1474-4422(19)30079-1]">Wardlaw 2019</a>). Following a lacunar stroke (a form of cSVD), antithrombotic therapy is used to prevent further stroke. Whether this antithrombotic therapy has any effect on the progression or manifestation of the underlying cSVD is unclear. </p> <p>The pathological changes of cSVD can be visualised using magnetic resonance imaging (MRI) or computed tomography (CT) brain scanning. MRI is the preferred tool for assessing cSVD owing to its greater sensitivity to the essential neuroimaging features of cSVD (<a href="./references#CD012269-bbs2-0053" title="NorrvingB . Evolving concept of small vessel disease through advanced brain imaging. Journal of Stroke2015;17:94-100. [DOI: 10.5853/jos.2015.17.2.94]">Norrving 2015</a>). Classical features of cSVD include subcortical infarcts, lacunes, white matter hyperintensities, prominent perivascular spaces, cerebral microbleeds and atrophy (<a href="./references#CD012269-bbs2-0026" title="ArbaF , QuinnTJ , HankeyGJ , LeesKR , WardlawJM , AliM , et al. Enlarged perivascular spaces and cognitive impairment after stroke and transient ischemic attack. International Journal of Stroke2018;13:47-56. [DOI: 10.1177/1747493016666091]">Arba 2018</a>; <a href="./references#CD012269-bbs2-0031" title="BoutetC , Rouffiange-LeclairL , SchneiderF , CamdessanchéJP , AntoineJC , BarralFG . Visual assessment of age-related white matter hyperintensities using FLAIR images at 3T: inter- and intra-rater agreement. Neurodegenerative Diseases2016;16:279-83. [DOI: 10.1159/000441420]">Boutet 2016</a>; <a href="./references#CD012269-bbs2-0051" title="MokV , KimJS . Prevention and management of cerebral small vessel disease. Journal of Stroke2015;17:111-22. [DOI: 10.5853/jos.2015.17.2.111]">Mok 2015</a>).  </p> <p>cSVD lesions may be associated with all‐cause dementia, although the supporting evidence is not consistent (<a href="./references#CD012269-bbs2-0052" title="MortamaisM , ArteroS , RitchieK . Cerebral white matter hyperintensities in the prediction of cognitive decline and incident dementia. International Review of Psychiatry2013;25:686-98. [DOI: 10.3109/09540261.2013.838151]">Mortamais 2013</a>). The estimated proportion of dementia with contribution from cSVD ranges from 36% to 67% (<a href="./references#CD012269-bbs2-0040" title="Grau-OlivaresM , ArboixA . Mild cognitive impairment in stroke patients with ischaemic cerebral small-vessel disease: a forerunner of vascular dementia?Expert Review of Neurotherapeutics2009;9:1201-17. [DOI: 10.1586/ern.09.73]">Grau‐Olivares 2009</a>). Imaging evidence of cSVD is often seen in vascular dementia but the process may also be important in the pathogenesis of other types of dementia. Although the pathogenesis of Alzheimer's disease remains incompletely understood (<a href="./references#CD012269-bbs2-0044" title="Jack CR Jr, KnopmanDS , JagustWJ , ShawLM , AisenPS , WeinerMW , et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurology2010;9:119-28. [DOI: 10.1016/S1474-4422(09)70299-6]">Jack 2010</a>), there is increasing support for a potential vascular basis (<a href="./references#CD012269-bbs2-0039" title="GrammasP . Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease. Journal of Neuroinflammation2011;8:26. [DOI: 10.1186/1742-2094-8-26]">Grammas 2011</a>). Autopsy studies have demonstrated important interactions between cSVD and Alzheimer's pathology (<a href="./references#CD012269-bbs2-0042" title="IadecolaC . The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathology2010;120:287-96. [DOI: 10.1007/s00401-010-0718-6]">Iadecola 2010</a>), and cSVD risk factors such as diabetes and hypertension appear to be independent predictors of Alzheimer's disease (<a href="./references#CD012269-bbs2-0025" title="AkinyemiRO , Mukaetova-LadinskaEB , AttemsJ , IharaM , KalariaRN . Vascular risk factors and neurodegeneration in ageing related dementias: Alzheimer's disease and vascular dementia. Current Alzheimer Research2013;10:642-53.">Akinyemi 2013</a>). Among people with stroke of mild‐to‐moderate severity, MRI evidence of cSVD and medial temporal lobe atrophy (one of the imaging indicators of Alzheimer's pathology) are highly prevalent and can predict post‐stroke dementia at two years (<a href="./references#CD012269-bbs2-0046" title="KwanJS , MakSF , HuiR , SoK , HarWY , AzmanR , et al. Prevalence and clinical impact of white matter hyperintensities, cerebral microbleeds, and medial temporal lobe atrophy on short- and long-term outcomes after stroke rehabilitation. Hong Kong Medical Journal2016;22(Suppl 1):28. [hdl.handle.net/10722/225697]">Kwan 2016</a>). </p> <p>Many experts are already calling for improved vascular risk management for the primary prevention of dementia including Alzheimer's disease (<a href="./references#CD012269-bbs2-0057" title="SafourisA , PsaltopoulouT , SergentanisTN , BoutatiE , KapakiE , TsivgoulisG . Vascular risk factors and Alzheimer's disease pathogenesis: are conventional pharmacological approaches protective for cognitive decline progression?CNS &amp; Neurological Disorders Drug Targets2015;14:257-69.">Safouris 2015</a>), yet the effectiveness of these strategies in altering the trajectory of dementia‐related pathologies and cognitive decline remains unclear. The following clinical scenario is a common one: an older adult has no evidence of cognitive impairment or only a minor cognitive complaint but is keen to reduce their risk of developing dementia in the future. They have cSVD on an MRI scan performed for another reason, for example headache. For this patient: s<i>hould antithrombotic therapy be started to prevent future cognitive decline?</i> In this review, we looked into the effectiveness of antithrombotic therapy for both symptomatic and asymptomatic cSVD for the prevention of (further) cognitive decline and dementia.  </p> </section> <section id="CD012269-sec-0011"> <h3 class="title" id="CD012269-sec-0011">Description of the intervention</h3> <p>Antithrombotic therapy reduces the formation of thrombus through acting on one or more aspect of the thrombotic cascade. Based on their mode of action, antithrombotic agents are categorised as antiplatelets, anticoagulants and fibrinolytic agents. In this review, we do not consider fibrinolytics as they tend to be used in the acute setting only and would not be used as a longer‐term primary or secondary preventive intervention.  </p> <p>Antiplatelet agents include: cyclo‐oxygenase inhibitors (e.g. aspirin); inhibitors of phosphodiesterases III and V and inhibitors of adenosine uptake by red cells (e.g. cilostazol, dipyridamole); blockade of the platelet ADP P2Y12 receptor (e.g. clopidogrel, prasugrel, ticagrelor); blockade of glycoprotein IIb/IIIa receptors (e.g. abciximab); and increasing nitric oxide levels (e.g. triflusal) (<a href="./references#CD012269-bbs2-0037" title="GeeganageC , WilcoxR , BathPM . Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis. BMC Medicine2010;8:36. [DOI: 10.1186/1741-7015-8-36]">Geeganage 2010</a>). Oral anticoagulants include traditional vitamin K antagonists (e.g. warfarin) and direct oral anticoagulants (DOACs). DOACs include agents that inhibit activated factor Xa (e.g. apixaban, rivaroxaban and edoxaban) or thrombin (e.g. dabigatran) (<a href="./references#CD012269-bbs2-0047" title="LipGY , LaneDA . Stroke prevention in atrial fibrillation: a systematic review. JAMA2015;313:1950-62. [DOI: 10.1001/jama.2015.4369]">Lip 2015</a>). </p> </section> <section id="CD012269-sec-0012"> <h3 class="title" id="CD012269-sec-0012">How the intervention might work</h3> <p>Antiplatelet agents are the usual treatment for secondary stroke prevention after an ischaemic stroke (<a href="./references#CD012269-bbs2-0027" title="Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ2002;324:71-86. [PMID: 11786451]">ATC 2002</a>), including for lacunar (subcortical) stroke. Different regimens have been evaluated in this context, including both single agents and combinations of agents (<a href="./references#CD012269-bbs2-0043" title="IshidaK , MesséSR . Antiplatelet strategies for secondary prevention of stroke and TIA. Current Atherosclerosis Report2014;16:449. [DOI: 10.1007/s11883-014-0449-6]">Ishida 2014</a>). Increasing potency of antiplatelet can often be accompanied by increasing risk of bleeding. Thus the use of antiplatelet agents in people with cSVD needs to balance the potential benefit against risks (<a href="./references#CD012269-bbs2-0051" title="MokV , KimJS . Prevention and management of cerebral small vessel disease. Journal of Stroke2015;17:111-22. [DOI: 10.5853/jos.2015.17.2.111]">Mok 2015</a>).  </p> <p>Oral anticoagulants are the standard treatment for the primary and secondary prevention of stroke in high‐risk patients with atrial fibrillation or certain other cardioembolic stroke aetiologies (<a href="./references#CD012269-bbs2-0032" title="CameronC , CoyleD , RichterT , KellyS , GauthierK , SteinerS , et al. Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. British Medical Journal Open2014;4:e004301. [DOI: 10.1136/bmjopen-2013-004301]">Cameron 2014</a>). In this review, we also included participants with cardioembolic stroke so long as they had concomitant cSVD, as we hypothesised that the pathophysiological mechanism for cognitive decline is comparable for this group. </p> <p>Since antithrombotic agents have demonstrated efficacy in the prevention of symptomatic ischaemic stroke, it seems plausible that they might also prevent the asymptomatic (silent) infarcts that are thought to be part of cSVD. We hypothesised that this could in turn prevent the clinical manifestations of cSVD including cognitive decline.  </p> </section> <section id="CD012269-sec-0013"> <h3 class="title" id="CD012269-sec-0013">Why it is important to do this review</h3> <p>There is currently no evidence‐based or licensed drug treatment for the prevention of cognitive decline and dementia. If antithrombotic agents could prevent or delay cognitive impairment associated with cSVD, this could be an inexpensive intervention for the many people living with this condition. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012269-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012269-sec-0014"></div> <p>To assess the effects of antithrombotic therapy for prevention of cognitive decline in people with small vessel disease on neuroimaging but without dementia. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012269-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012269-sec-0015"></div> <section id="CD012269-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012269-sec-0017"> <h4 class="title">Types of studies</h4> <p>For this review, we considered only randomised controlled trials (RCTs).</p> </section> <section id="CD012269-sec-0018"> <h4 class="title">Types of participants</h4> <p>To be eligible for inclusion, participants had to have evidence of cSVD on neuroimaging but no dementia, using the following definitions. </p> <p> <ol id="CD012269-list-0001"> <li> <p>Presence of cSVD on neuroimaging (CT or MRI). Where possible, we used the definitions of the STandards for ReportIng Vascular changes on nEuroimaging (STRIVE) guidance as a reference (<a href="./references#CD012269-bbs2-0061" title="WardlawJM , SmithEE , BiesselsGJ , CordonnierC , FazekasF , FrayneR , et al, STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurology2013;12:822-38. [DOI: 10.1016/S1474-4422(13)70124-8]">Wardlaw 2013</a>), but a degree of flexibility of interpretation was employed and noted. Features of cSVD are often measured on ordinal scales; we included those studies where the degree of cSVD change was at least 'mild' (e.g. greater than 1 on the Fazekas scale in assessing white matter hyperintensity). In studies of mixed populations, at least 75% of the participants had to have imaging evidence of cSVD. </p> </li> <li> <p>Absence of dementia of any cause. Where possible, we aimed to include studies using internationally accepted diagnostic criteria for dementia, however a degree of flexibility was needed because of heterogeneity of the operationalisation of this exclusion criterion in the included studies. Therefore, we also accepted cognitive testing that was plausible to detect incipient or existing dementia. </p> </li> </ol> </p> <p>Participants with or without a history of symptomatic stroke were eligible for inclusion, as long as they met the above criteria for cSVD on neuroimaging and no dementia.  </p> </section> <section id="CD012269-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Antithrombotic therapy included the following three treatment regimens.</p> <p> <ol id="CD012269-list-0002"> <li> <p>Antiplatelet agents (as monotherapy or combination therapy).</p> </li> <li> <p>Oral anticoagulants (vitamin K antagonists or DOACs).</p> </li> <li> <p>Antiplatelet agent(s) combined with oral anticoagulant(s).</p> </li> </ol> </p> <p>We considered all studies that compared antithrombotic therapy (administered for at least six months) to no antithrombotic therapy (either placebo or treatment as usual), or that compared different antithrombotic therapy regimens. We did not specify any restrictions based on dose, frequency or method of administration. We opted for a minimal intervention duration of 24 weeks as cognitive decline due to cSVD is a slow process and little effect can be expected on cognitive decline for shorter intervention durations. </p> </section> <section id="CD012269-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We included the following primary and secondary outcomes.</p> <section id="CD012269-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD012269-list-0003"> <li> <p>Change in cognitive function between baseline and final follow‐up using validated cognitive assessment measures. </p> </li> <li> <p>Incident dementia of any cause as defined by internationally accepted diagnostic criteria.</p> </li> <li> <p>Bleeding, including new intracranial haemorrhagic events (intracerebral, subdural, subarachnoid and extradural) or major extracranial haemorrhagic events. </p> </li> </ol> </p> </section> <section id="CD012269-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD012269-list-0004"> <li> <p>Functional outcome using validated functional assessment measures.</p> </li> <li> <p>Incident ischaemic stroke or transient ischaemic attack.</p> </li> <li> <p>Death.</p> </li> <li> <p>Adverse events (excluding bleeding, as this is already reported as primary outcome).</p> </li> <li> <p>Withdrawal from the allocated treatment within the scheduled follow‐up period.</p> </li> <li> <p>New cerebral microbleeds on repeat neuroimaging.</p> </li> <li> <p>Incident mild cognitive impairment (MCI).</p> </li> </ol> </p> </section> </section> </section> <section id="CD012269-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>We used the following search method to identify studies.</p> <section id="CD012269-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched ALOIS (<a href="https://alois.medsci.ox.ac.uk" target="_blank">alois.medsci.ox.ac.uk</a>) – the Cochrane Dementia and Cognitive Improvement Review Group's Specialised Register, and the Cochrane Stroke Group's Specialised Register. </p> <p>ALOIS is maintained by the Review Group's Information Specialist and contains dementia and cognitive improvement studies identified from: </p> <p> <ol id="CD012269-list-0005"> <li> <p>monthly searches of several major healthcare databases: MEDLINE, Embase, CINAHL, PsycINFO and Lilacs; </p> </li> <li> <p>monthly searches of the trial registers: the World Health Organization (WHO) International Clinical Trials Registry Platform (which covers ClinicalTrials.gov, ISRCTN, the Chinese Clinical Trials Register, the German Clinical Trials Register, the Iranian Registry of Clinical Trials, and the Netherlands National Trials Register, plus others) and ClinicalTrials.gov; </p> </li> <li> <p>quarterly search of the Cochrane Library's Central Register of Controlled Trials (CENTRAL);</p> </li> <li> <p>six‐monthly searches of several grey literature sources from ISI Web of Science Core Collection. </p> </li> </ol> </p> <p>Details of the search strategies used for the retrieval of reports of trials from the healthcare databases, CENTRAL and conference proceedings can be viewed in the 'Methods used in reviews' section within the editorial information about the Dementia and Cognitive Improvement Group (<a href="https://dementia.cochrane.org/resources-review-authors" target="_blank">dementia.cochrane.org/resources-review-authors</a>). We performed additional searches in many of the sources listed above to ensure that the search for the review was as up‐to‐date and comprehensive as possible. </p> <p>We recognised that potentially relevant data may be available through subgroup analysis of stroke trials, for example a study of antiplatelet in stroke that had cognitive outcome data and where a subgroup of participant with lacunar stroke (a form of cSVD) could be derived. We worked with the Cochrane Stroke Group and handsearched all antithrombotic trials in their Centralised Register. <br/><br/>Our search strategies used are described in <a href="./appendices#CD012269-sec-0079">Appendix 1</a>. The most recent search was carried out on 21 July 2021. </p> </section> <section id="CD012269-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of articles retrieved from the above searches. For included studies, we retrieved additionally published subpapers where appropriate, to ensure a comprehensive data extraction. Where clarification of information was needed, we attempted to contact the investigators of the relevant studies. </p> </section> </section> <section id="CD012269-sec-0026"> <h3 class="title" id="CD012269-sec-0026">Data collection and analysis</h3> <p>We used the following method for data collection and data analysis.</p> <section id="CD012269-sec-0027"> <h4 class="title">Selection of studies</h4> <p>A minimum of two review authors independently screened all titles and abstracts of publications identified by the searches to assess their eligibility. Publications that clearly did not meet the inclusion criteria were excluded at this stage. We retrieved the full‐text versions of potentially relevant studies. A minimum of two review authors independently assessed each full‐text study according to the prespecified selection criteria. Disagreements were resolved by discussion. </p> </section> <section id="CD012269-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>A minimum of two authors independently extracted data from the published reports. Disagreements were resolved by discussion. </p> </section> <section id="CD012269-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>A minimum of two review authors independently assessed risk of bias for each included study. We used the RoB 1 tool as described in the original <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012269-bbs2-0041" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>)<i>. </i>This RoB assessment considered five domains: selection bias, performance bias, attrition bias, detection bias and reporting bias. Domains were assessed for eligible papers and we classified them as low or high risk of bias. Where there was insufficient detail in a study to assess the risk, we reported it as unclear.  </p> </section> <section id="CD012269-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous data, we expressed relative treatment effects as odds ratio (OR) or risk ratios (RR) with 95% confidence intervals (CI). For continuous data, we used mean differences (MD) with 95% CIs. </p> </section> <section id="CD012269-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>The participant was the unit of analysis. Where studies reported outcomes at more than one time point, we used the outcome data from the end of the intervention period where possible. </p> </section> <section id="CD012269-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We reported the amount of missing outcome data in each trial. When reporting trialists' own analyses, we favoured intention‐to‐treat analyses and reported any imputation methods. </p> </section> <section id="CD012269-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>Assessment of heterogeneity was performed in accordance with the guidance in Chapter 9 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012269-bbs2-0041" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). We assessed clinical heterogeneity and considered the characteristics of the participants, how cSVD was diagnosed, the type of antithrombotic agents tested, and how the outcomes were assessed and reported. </p> </section> <section id="CD012269-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>If the trial data had allowed, we would have used visual inspection of funnel plot analyses to assess for potential reporting biases. However, for this review, there were insufficient studies to allow for this analysis.  </p> </section> <section id="CD012269-sec-0035"> <h4 class="title">Data synthesis</h4> <p>Due to the small number of eligible studies and the significant heterogeneity between them, we were unable to conduct any meta‐analyses to derive summary treatment effects. We instead described the individual studies using a narrative approach and created a summary table detailing the potential class effects of antithrombotic therapy.  </p> </section> <section id="CD012269-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We did not conduct any subgroup analyses. </p> </section> <section id="CD012269-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We did not conduct any sensitivity analyses.</p> </section> <section id="CD012269-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADE approach to assess the certainty of the supporting evidence behind each estimate of treatment effect (<a href="./references#CD012269-bbs2-0058" title="SchünemannHJ , OxmanAD , BrozekJ , GlasziouP , JaeschkeR , VistGE , et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ2008;336:1106-10. [DOI: 10.1136/bmj.a139]">Schünemann 2008</a>). We presented key findings of the review including a summary of the amount of data, the magnitude of the effect size and the overall certainty of the evidence, in summary of findings tables, created using GRADEpro software (<a href="./references#CD012269-bbs2-0038" title="GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), accessed 1 December 2021. Available at gradepro.org.">GRADEpro GDT</a>). We had preselected the following outcomes for inclusion in the summary of findings tables. </p> <p> <ol id="CD012269-list-0006"> <li> <p>Change in cognitive function from baseline.</p> </li> <li> <p>Incident dementia.</p> </li> <li> <p>Major bleeding events.</p> </li> <li> <p>Functional outcome.</p> </li> <li> <p>Ischaemic stroke or transient ischaemic attack.</p> </li> <li> <p>Adverse events (excluding bleeding).</p> </li> <li> <p>Withdrawal from the allocated treatment.</p> </li> </ol> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012269-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012269-sec-0039"></div> <section id="CD012269-sec-0040"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD012269-sec-0089" title="">Characteristics of included studies</a>, <a href="./references#CD012269-sec-0090" title="">Characteristics of excluded studies</a>, <a href="./references#CD012269-sec-0091" title="">Characteristics of studies awaiting classification</a>, and <a href="./references#CD012269-sec-0092" title="">Characteristics of ongoing studies</a> tables for details of the studies considered for this review. </p> <section id="CD012269-sec-0041"> <h4 class="title">Results of the search</h4> <p>The Information Specialists of the Cochrane Dementia and Cognitive Improvement Group performed electronic searches on 7 July 2016, 4 May 2017, 22 June 2018, 6 June 2019, 16 September 2020 and 21 July 2021. In total, we retrieved 9658 results through database searching and six results through other sources. After deduplication, there remained 8084 records, 8064 of which we excluded at the title and abstract stage. We downloaded the full‐texts or sought further information for 23 articles to assess their eligibility. See <a href="#CD012269-fig-0001">Figure 1</a> and <a href="./appendices#CD012269-sec-0079">Appendix 1</a> for more details. </p> <div class="figure" id="CD012269-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="original image" data-id="CD012269-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012269.pub2/media/CDSR/CD012269/image_n/nCD012269-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <p>The review includes three studies (<a href="./references#CD012269-bbs2-0001" title="JiaJ , WeiC , LiangJ , ZhouA , ZuoX , SongH , et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischaemic small vessel disease: a multicentre, randomised, double-blind, placebo-controlled trial. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2016;12(2):89-99. [DOI: 10.1016/j.jalz.2015.04.010] [PMID: 26086183]">Jia 2016</a>; <a href="./references#CD012269-bbs2-0002" title="MaestriniI , AltieriM , ClementeLD , VicenziniE , PantanoP , RazE , et al. Longitudinal study on low-dose aspirin versus placebo administration in silent brain infarcts: the SILENCE study. Stroke Research and Treatment2018;2018(7532403):1-9. [DOI: doi.org/10.1155/2018/7532403]">Maestrini SILENCE 2018</a>; <a href="./references#CD012269-bbs2-0003" title="PearceLA , McClureLA , AndersonDC , JacovaC , SharmaM , HartRG , et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurology2014;13:1177-85. [CENTRAL: PMC4284947] [DOI: 10.1016/S1474-4422(14)70224-8]SharmaM , PearceLA , BenaventeOR , AndersonDC , ConnollySJ , PalacioS , et al. Predictors of mortality in patients with lacunar stroke in the Secondary Prevention of Small Subcortical Strokes trial. Stroke; a Journal of Cerebral Circulation2014;45(10):2989–94. [CENTRAL: PMC4175186] [DOI: doi.org/10.1161/STROKEAHA.114.005789] [PMID: 25158772]The SPS3 Investigators, BenaventeOR , CoffeyCS , ConwitR , HartRG , McClureLA , PearceLA , et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. New England Journal of Medicine2012;367(9):817-25. [DOI: 10.1056/NEJMoa1204133]">Pearce SPS3 2014</a>). We excluded 11 studies because they did not meet our inclusion criteria (<a href="./references#CD012269-bbs2-0005" title="O'DonnellMJ ,  Eikelboom JW,  Yusuf S,  Diener HC, HartRG , SmithEE , et al. Effect of apixaban on brain infarction and microbleeds: AVERROES – MRI assessment study. American Heart Journal2016;178:145-50. [DOI: 10.1016/j.ahj.2016.03.019]">AVERROES‐MRI assessment study</a>; <a href="./references#CD012269-bbs2-0006" title="SharmaM , HartRG , SmithEE , BoschJ , EikelboomJW , ConnollySJ ,   et al. Rivaroxaban for prevention of covert brain infarcts and cognitive decline: the COMPASS MRI substudy. Stroke2020;51:2901-9. ">COMPASS MRI</a>; <a href="./references#CD012269-bbs2-0007" title="DouiriA , McKevittC , EmmettES , RuddAG , WolfeCD . Long-term effects of secondary prevention on cognitive function in stroke patients. Circulation2013;128(12):1341-8. [DOI: 10.1161/CIRCULATIONAHA.113.002236] [PMID: 23935013]">Douiri 2013</a>; <a href="./references#CD012269-bbs2-0008" title="HanSW ,   LeeS , KimSH , LeeJH ,  KimGS , KimO , et al. Effect of cilostazol in acute lacunar infarction based on pulsatility index of transcranial Doppler (ECLIPse): a multicenter, randomized, double-blind, placebo-controlled trial. European Neurology2013;69:33-40. [DOI: DOI: 10.1159/000338247]">Han 2013</a>; <a href="./references#CD012269-bbs2-0009" title="JacobsV , MayHT , BairTL , AndersonJL , CrandallBG , CutlerM , et al . Dementia and stroke rates were lower among patients receiving long-term anticoagulation therapy with novel oral anticoagulants compared to warfarin. American Journal of Cardiology2015;118(2):210-4. [DOI: 10.1016/j.amjcard.2016.04.039] [PMID: 27236255]">Jacobs 2015</a>; <a href="./references#CD012269-bbs2-0010" title="KwokCS , ShoamaneshA , CopleyHC , MyintPK , LokeYK , BenaventeOR . Efficacy of antiplatelet therapy in secondary prevention following lacunar stroke pooled analysis of randomised trials. Stroke2015;46(4):1014. [DOI: 10.1161/STROKEAHA.114.008422] [PMID: 25721018]">Kwok 2015</a>; <a href="./references#CD012269-bbs2-0011" title="KwonHM , LynnMJ , TuranTN , DerdeynCP , FiorellaD , LaneBF , et al, Sammpris Investigators. Frequency, risk factors, and outcome of coexistent small vessel disease and intracranial arterial stenosis: results from the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial. JAMA Neurology2016;73:36-42. [DOI: 10.1001/jamaneurol.2015.3145.] [PMID: 26618534]">Kwon 2016</a>; <a href="./references#CD012269-bbs2-0012" title="BlairGW , AppletonJP , FlahertyK , DoubalF , SpriggN , DooleyR , et al. Tolerability, safety and intermediary pharmacological effects of cilostazol and isosorbide mononitrate, alone and combined, in patients with lacunar ischaemic stroke: the LACunar Intervention-1 (LACI-1) trial, a randomised clinical trial. Lancet EClinical Medicine2019;11:34-43. [DOI: doi.org/10.1016/j.eclinm.2019.04.001]">LACI‐1</a>; <a href="./references#CD012269-bbs2-0013" title="Shindo-TagawaT , YamasakiY , YoshidaS , KajimotoY , TsujinoT , HakuiN , et al. A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with type II diabetes. Diabetologia2002;45:188-94. ">Shinod‐Tagawa 2002</a>; <a href="./references#CD012269-bbs2-0014" title="XuYY , ZongL , ZhangC , PanY , JingJ , MengX , et al, on behalf of the CHANCE Investigators. The association of white matter hyperintensities with stroke outcomes and antiplatelet therapy in minor stroke patients. Annals of Translational Medicine2020;8:331. [DOI: 10.21037/atm.2020.02.137]">Xu 2020</a>; <a href="./references#CD012269-bbs2-0015" title="ZhangY , ZhangZ , YangB , LiY , ZhangQ , QuQ , et al. Effects of antiplatelet agents on functional outcome and cognitive status in patients with acute ischaemic stroke. International Journal of Gerontology2014;8(4):189-92. [DOI: 10.1016/j.ijge.2013.12.005]">Zhang 2014</a>). There are eight ongoing studies (<a href="./references#CD012269-bbs2-0004" title="WardSA , RanigaP , FerrisNJ , WoodsRL , StoreyE , BaileyMJ , et al. ASPREE-NEURO study protocol: a randomized controlled trial to determine the effect of low-dose aspirin on cerebral microbleeds, white matter hyperintensities, cognition, and stroke in the healthy elderly. International Journal of Stroke2017;12(1):108-13. ">ASPREE‐NEURO</a>; <a href="./references#CD012269-bbs2-0017" title="NCT03061006. Impact of anticoagulation therapy on the cognitive decline and dementia in patients with non-valvular atrial fibrillation (CAF). clinicaltrials.gov/ct2/show/NCT03061006 (first received 23 February 2017). ">CAF</a>; <a href="./references#CD012269-bbs2-0018" title="NCT01932203. Efficacy study of cilostazol and aspirin on cerebral small vessel disease (Challenge). clinicaltrials.gov/ct2/show/NCT01932203 (first received 30 August 2013). ">CHALLENGE</a>; <a href="./references#CD012269-bbs2-0019" title="ChiCTR-TCS-14005054. Cilostazol in retarding progression of cerebral white matter hyperintensities. www2.ccrb.cuhk.edu.hk/registry/public/269/history/1495 (first received 21 January 2014). ">ChiCTR‐TCS‐14005054</a>; <a href="./references#CD012269-bbs2-0021" title="NCT03451591. LACunar Intervention (LACI-2) Trial-2 (LACI-2). clinicaltrials.gov/ct2/show/NCT03451591 (first received 2 March 2018). ">LACI‐2</a>; <a href="./references#CD012269-bbs2-0022" title="NCT01932203. Efficacy study of cilostazol and aspirin on cerebral small vessel disease (Challenge). clinicaltrials.gov/ct2/show/NCT01932203 (first received 30 August 2013). ">NCT01932203</a>; <a href="./references#CD012269-bbs2-0023" title="YuKH , HongKS , OhMS , LeeJ , LeeJS , Kwon Su. Design and rationale for a cognitive outcome substudy in ischemic stroke patients with high risk of cerebral hemorrhage. Journal of Stroke and Cerebrovascular Diseases2016;25(8):2061-6. [DOI: dx.doi.org/10.1016/j.jstrokecerebrovasdis.2016.04.028]">PICASSO‐Cog</a>; <a href="./references#CD012269-bbs2-0024" title="ReidCM , StoreyE , BudgeMM . Aspirin for the prevention of cognitive decline in the elderly: rationale and design of a neuro-vascular imaging study (ENVIS-ion). BMC Neurology2012;12(3):1-9. ">Reid ENVIS‐ion 2012</a>) and one study is awaiting classification as we were unable to contact the author for the necessary details (<a href="./references#CD012269-bbs2-0016" title="NCT00847860. Cilostazol verse aspirin for vascular dementia in poststroke patients with white matter lesions (CAVAD). clinicaltrials.gov/ct2/show/NCT00847860 (first received 19 February 2009). ">CAVAD</a>). Details on these ongoing studies is reported in <a href="./references#CD012269-bbs1-0004" title="">Ongoing studies</a>. No studies that looked at white matter hyperintensity or lacunar infarctions only were identified. </p> <p>See <a href="#CD012269-fig-0001">Figure 1</a> PRISMA Study flow diagram for the summary of our selection process. </p> </section> <section id="CD012269-sec-0042"> <h4 class="title">Included studies</h4> <p>We included three RCTs (3384 participants) (<a href="./references#CD012269-bbs2-0001" title="JiaJ , WeiC , LiangJ , ZhouA , ZuoX , SongH , et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischaemic small vessel disease: a multicentre, randomised, double-blind, placebo-controlled trial. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2016;12(2):89-99. [DOI: 10.1016/j.jalz.2015.04.010] [PMID: 26086183]">Jia 2016</a>; <a href="./references#CD012269-bbs2-0002" title="MaestriniI , AltieriM , ClementeLD , VicenziniE , PantanoP , RazE , et al. Longitudinal study on low-dose aspirin versus placebo administration in silent brain infarcts: the SILENCE study. Stroke Research and Treatment2018;2018(7532403):1-9. [DOI: doi.org/10.1155/2018/7532403]">Maestrini SILENCE 2018</a>; <a href="./references#CD012269-bbs2-0003" title="PearceLA , McClureLA , AndersonDC , JacovaC , SharmaM , HartRG , et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurology2014;13:1177-85. [CENTRAL: PMC4284947] [DOI: 10.1016/S1474-4422(14)70224-8]SharmaM , PearceLA , BenaventeOR , AndersonDC , ConnollySJ , PalacioS , et al. Predictors of mortality in patients with lacunar stroke in the Secondary Prevention of Small Subcortical Strokes trial. Stroke; a Journal of Cerebral Circulation2014;45(10):2989–94. [CENTRAL: PMC4175186] [DOI: doi.org/10.1161/STROKEAHA.114.005789] [PMID: 25158772]The SPS3 Investigators, BenaventeOR , CoffeyCS , ConwitR , HartRG , McClureLA , PearceLA , et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. New England Journal of Medicine2012;367(9):817-25. [DOI: 10.1056/NEJMoa1204133]">Pearce SPS3 2014</a>). </p> <section id="CD012269-sec-0043"> <h5 class="title">Study design</h5> <p><a href="./references#CD012269-bbs2-0001" title="JiaJ , WeiC , LiangJ , ZhouA , ZuoX , SongH , et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischaemic small vessel disease: a multicentre, randomised, double-blind, placebo-controlled trial. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2016;12(2):89-99. [DOI: 10.1016/j.jalz.2015.04.010] [PMID: 26086183]">Jia 2016</a> was a randomised, double‐blind, placebo‐controlled trial that assessed the effects of DL‐3‐n‐butylphthalide in participants with vascular cognitive impairment without dementia, caused by subcortical ischaemic cSVD. DL‐3‐n‐butylphthalide has multimodal effects and while not classically considered an antithrombotic agent, one of its actions is inhibition of platelet aggregation.The intervention period was 24 weeks and the follow‐up duration six months.  </p> <p>The SILENCE trial was a randomised, placebo‐controlled trial that assessed aspirin in a population with silent brain infarcts (<a href="./references#CD012269-bbs2-0002" title="MaestriniI , AltieriM , ClementeLD , VicenziniE , PantanoP , RazE , et al. Longitudinal study on low-dose aspirin versus placebo administration in silent brain infarcts: the SILENCE study. Stroke Research and Treatment2018;2018(7532403):1-9. [DOI: doi.org/10.1155/2018/7532403]">Maestrini SILENCE 2018</a>). A large proportion of 33 participants (40%) refused randomisation and were followed up as an observational cohort. The intervention and follow‐up duration was four years.  </p> <p>The Secondary Prevention of Small Subcortical Strokes (SPS3) trial was a randomised, placebo‐controlled, multicentre clinical trial that studied the effects of dual (aspirin plus clopidogrel) versus single (aspirin alone) antiplatelet therapy (<a href="./references#CD012269-bbs2-0003" title="PearceLA , McClureLA , AndersonDC , JacovaC , SharmaM , HartRG , et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurology2014;13:1177-85. [CENTRAL: PMC4284947] [DOI: 10.1016/S1474-4422(14)70224-8]SharmaM , PearceLA , BenaventeOR , AndersonDC , ConnollySJ , PalacioS , et al. Predictors of mortality in patients with lacunar stroke in the Secondary Prevention of Small Subcortical Strokes trial. Stroke; a Journal of Cerebral Circulation2014;45(10):2989–94. [CENTRAL: PMC4175186] [DOI: doi.org/10.1161/STROKEAHA.114.005789] [PMID: 25158772]The SPS3 Investigators, BenaventeOR , CoffeyCS , ConwitR , HartRG , McClureLA , PearceLA , et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. New England Journal of Medicine2012;367(9):817-25. [DOI: 10.1056/NEJMoa1204133]">Pearce SPS3 2014</a>). The intervention duration was three years and the median follow‐up for cognitive outcomes was 3.4 years.  </p> </section> <section id="CD012269-sec-0044"> <h5 class="title">Participants</h5> <p><a href="./references#CD012269-bbs2-0001" title="JiaJ , WeiC , LiangJ , ZhouA , ZuoX , SongH , et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischaemic small vessel disease: a multicentre, randomised, double-blind, placebo-controlled trial. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2016;12(2):89-99. [DOI: 10.1016/j.jalz.2015.04.010] [PMID: 26086183]">Jia 2016</a> assessed 563 people at 15 Chinese academic medical centres and recruited 280 participants aged 50 to 70 years who had a diagnosis of subcortical vascular cognitive impairment with cSVD but without dementia. Of these participants, 76% had a history of stroke at baseline. Participants had subjective cognitive complaints or evidence of cognitive decline from an informant, but not sufficient to warrant a diagnosis of dementia. Dementia at baseline was ruled out according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM‐IV), with Clinical Dementia Rating (CDR) 0.5 or greater on at least one domain and global score of 0.5 or less; a Mini‐Mental State Examination (MMSE) score of 20 or greater (with primary school education) or 24 or greater (with junior school education or above); and normal or slightly impaired activities of daily living (ADL) as defined by a total score of 1.5 or less on the three functional CDR domains (home and hobbies, community affairs and personal care). MRI inclusion criteria were evidence of cSVD, no cortical stroke and no medial temporal lobe atrophy. All participants were Han Chinese. </p> <p>The SILENCE RCT recruited people from Italian neurology clinics on the basis of MRI evidence of silent brain infarcts, with most included participants having infarcts in keeping with our cSVD definition (<a href="./references#CD012269-bbs2-0002" title="MaestriniI , AltieriM , ClementeLD , VicenziniE , PantanoP , RazE , et al. Longitudinal study on low-dose aspirin versus placebo administration in silent brain infarcts: the SILENCE study. Stroke Research and Treatment2018;2018(7532403):1-9. [DOI: doi.org/10.1155/2018/7532403]">Maestrini SILENCE 2018</a>). The study assessed 350 participants of whom 50 were enrolled in the RCT (aspirin group 24; placebo group 26) and 33 in a non‐randomised follow‐up. In this review, we include only data from the 50 randomised participants. </p> <p>The SPS3 study recruited 3020 participants aged 30 years or above from 81 clinical centres across seven different countries in the North and South Americas (<a href="./references#CD012269-bbs2-0003" title="PearceLA , McClureLA , AndersonDC , JacovaC , SharmaM , HartRG , et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurology2014;13:1177-85. [CENTRAL: PMC4284947] [DOI: 10.1016/S1474-4422(14)70224-8]SharmaM , PearceLA , BenaventeOR , AndersonDC , ConnollySJ , PalacioS , et al. Predictors of mortality in patients with lacunar stroke in the Secondary Prevention of Small Subcortical Strokes trial. Stroke; a Journal of Cerebral Circulation2014;45(10):2989–94. [CENTRAL: PMC4175186] [DOI: doi.org/10.1161/STROKEAHA.114.005789] [PMID: 25158772]The SPS3 Investigators, BenaventeOR , CoffeyCS , ConwitR , HartRG , McClureLA , PearceLA , et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. New England Journal of Medicine2012;367(9):817-25. [DOI: 10.1056/NEJMoa1204133]">Pearce SPS3 2014</a>). People who had recent symptomatic small subcortical stroke (within six months) with MRI confirmation were eligible for this trial. This study differed from <a href="./references#CD012269-bbs2-0001" title="JiaJ , WeiC , LiangJ , ZhouA , ZuoX , SongH , et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischaemic small vessel disease: a multicentre, randomised, double-blind, placebo-controlled trial. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2016;12(2):89-99. [DOI: 10.1016/j.jalz.2015.04.010] [PMID: 26086183]">Jia 2016</a> and <a href="./references#CD012269-bbs2-0002" title="MaestriniI , AltieriM , ClementeLD , VicenziniE , PantanoP , RazE , et al. Longitudinal study on low-dose aspirin versus placebo administration in silent brain infarcts: the SILENCE study. Stroke Research and Treatment2018;2018(7532403):1-9. [DOI: doi.org/10.1155/2018/7532403]">Maestrini SILENCE 2018</a> because it included participants with acute SVD. Of the 3020 recruited participants, 2916 had baseline assessment using the Cognitive Abilities Screening Instrument (CASI) and were included in the cognitive substudy. The study reported 26% of participants with incomplete testing (either left the study early or did not complete cognitive testing at their last follow‐up). Compared to those with complete data, they were more educated and more likely to have MCI at study entry. Participants were excluded if they had an MMSE score less than 24 points at baseline.  </p> </section> <section id="CD012269-sec-0045"> <h5 class="title">Intervention</h5> <p>Participants in <a href="./references#CD012269-bbs2-0001" title="JiaJ , WeiC , LiangJ , ZhouA , ZuoX , SongH , et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischaemic small vessel disease: a multicentre, randomised, double-blind, placebo-controlled trial. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2016;12(2):89-99. [DOI: 10.1016/j.jalz.2015.04.010] [PMID: 26086183]">Jia 2016</a> were randomly assigned to receive either DL‐3‐n‐butylphthalide capsule or placebo, taken orally three times daily for six months. The number of unused capsules were counted in the medicine bottles to assess drug compliance. Concomitant aspirin was used in 61.4% of the DL‐3‐n‐butylphthalide group and 65.7% of the placebo group. </p> <p>Participants in <a href="./references#CD012269-bbs2-0002" title="MaestriniI , AltieriM , ClementeLD , VicenziniE , PantanoP , RazE , et al. Longitudinal study on low-dose aspirin versus placebo administration in silent brain infarcts: the SILENCE study. Stroke Research and Treatment2018;2018(7532403):1-9. [DOI: doi.org/10.1155/2018/7532403]">Maestrini SILENCE 2018</a> were randomly assigned to receive either enteric‐coated aspirin 100 mg daily or placebo with identical appearance. </p> <p>Participants in <a href="./references#CD012269-bbs2-0003" title="PearceLA , McClureLA , AndersonDC , JacovaC , SharmaM , HartRG , et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurology2014;13:1177-85. [CENTRAL: PMC4284947] [DOI: 10.1016/S1474-4422(14)70224-8]SharmaM , PearceLA , BenaventeOR , AndersonDC , ConnollySJ , PalacioS , et al. Predictors of mortality in patients with lacunar stroke in the Secondary Prevention of Small Subcortical Strokes trial. Stroke; a Journal of Cerebral Circulation2014;45(10):2989–94. [CENTRAL: PMC4175186] [DOI: doi.org/10.1161/STROKEAHA.114.005789] [PMID: 25158772]The SPS3 Investigators, BenaventeOR , CoffeyCS , ConwitR , HartRG , McClureLA , PearceLA , et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. New England Journal of Medicine2012;367(9):817-25. [DOI: 10.1056/NEJMoa1204133]">Pearce SPS3 2014</a> were randomly assigned to receive either enteric‐coated aspirin 325 mg daily plus clopidogrel 75 mg daily or enteric‐coated aspirin 325 mg daily plus matching placebo. Compliance was measured by tablet counts, and follow‐up was five years. </p> </section> <section id="CD012269-sec-0046"> <h5 class="title">Outcome measures</h5> <p>The primary outcomes in <a href="./references#CD012269-bbs2-0001" title="JiaJ , WeiC , LiangJ , ZhouA , ZuoX , SongH , et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischaemic small vessel disease: a multicentre, randomised, double-blind, placebo-controlled trial. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2016;12(2):89-99. [DOI: 10.1016/j.jalz.2015.04.010] [PMID: 26086183]">Jia 2016</a> included Alzheimer's Disease Assessment Scale – Cognitive subscale (ADAS‐Cog; a 12‐item global cognitive score ranging from 0 (best) to 70 (worst)); and Clinician Interview‐Based Impression of Change‐Plus Caregiver Input (CIBIC‐plus; a global assessment of change based on a semi‐structured, patient/caregiver interview, with scores ranging from 1 to 7, where 1 is "very much improved", 4 is "no change", and 7 is "very much worse"). Secondary outcomes were MMSE (range 30 with higher scores indicates better performance), Clinical Dementia Rating (CDR) global score (range 0 = no impairment to 3 = severe impairment), CDR‐sum of boxes (CDR‐SB, range 0 to 18, with higher scores representing greater severity of cognitive and functional impairment), Neuropsychiatric Inventory (NPI, a composite symptom domain score ranging from 0 = absence of behavioural symptoms to 144 = maximum severity of behavioural symptoms), Chinese Activities of Daily Living (ADL; range 20–80, with higher scores indicating worse functioning) and adverse events. Assessments were at baseline, week 12 and week 24. </p> <p>The primary outcome in <a href="./references#CD012269-bbs2-0002" title="MaestriniI , AltieriM , ClementeLD , VicenziniE , PantanoP , RazE , et al. Longitudinal study on low-dose aspirin versus placebo administration in silent brain infarcts: the SILENCE study. Stroke Research and Treatment2018;2018(7532403):1-9. [DOI: doi.org/10.1155/2018/7532403]">Maestrini SILENCE 2018</a> was a composite of clinical and radiological stroke events. Secondary outcomes included change in cognition using a multidomain neuropsychological test battery and the MMSE, an unspecified ADL measure and adverse events. Assessments were performed annually over four years of follow‐up.  </p> <p>The primary outcomes in <a href="./references#CD012269-bbs2-0003" title="PearceLA , McClureLA , AndersonDC , JacovaC , SharmaM , HartRG , et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurology2014;13:1177-85. [CENTRAL: PMC4284947] [DOI: 10.1016/S1474-4422(14)70224-8]SharmaM , PearceLA , BenaventeOR , AndersonDC , ConnollySJ , PalacioS , et al. Predictors of mortality in patients with lacunar stroke in the Secondary Prevention of Small Subcortical Strokes trial. Stroke; a Journal of Cerebral Circulation2014;45(10):2989–94. [CENTRAL: PMC4175186] [DOI: doi.org/10.1161/STROKEAHA.114.005789] [PMID: 25158772]The SPS3 Investigators, BenaventeOR , CoffeyCS , ConwitR , HartRG , McClureLA , PearceLA , et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. New England Journal of Medicine2012;367(9):817-25. [DOI: 10.1056/NEJMoa1204133]">Pearce SPS3 2014</a> were recurrent stroke and bleeding. Cognitive function was a secondary outcome as measured by CASI; a global measure of cognition assessing attention, concentration, orientation, short‐term memory, long‐term memory, language abilities, visual construction, list‐generating fluency, abstraction and judgement, with scores of 0 to 100, with higher scores indicating better performance. The CASI assessment was performed annually during five years of follow‐up, and participants were only included in the cognitive substudy if they had at least one year of follow‐up. Incident MCI was recorded. MCI (definition derived in posthoc analysis) was defined psychometrically at entry and annually on the basis of test scores as no cognitive impairment, MCI (single amnestic), MCI (multidomain) and MCI (non‐amnestic). For a full description of MCI assessment see <a href="./references#CD012269-sec-0089" title="">Characteristics of included studies</a> table.  </p> </section> </section> <section id="CD012269-sec-0047"> <h4 class="title">Excluded studies</h4> <p>We excluded 12 studies as they did not meet our predefined inclusion criteria. For the full details of the reasons for exclusion, see <a href="./references#CD012269-sec-0090" title="">Characteristics of excluded studies</a> table. The most common reasons for exclusion were using a non‐randomised controlled trial design (<a href="./references#CD012269-bbs2-0007" title="DouiriA , McKevittC , EmmettES , RuddAG , WolfeCD . Long-term effects of secondary prevention on cognitive function in stroke patients. Circulation2013;128(12):1341-8. [DOI: 10.1161/CIRCULATIONAHA.113.002236] [PMID: 23935013]">Douiri 2013</a>; <a href="./references#CD012269-bbs2-0009" title="JacobsV , MayHT , BairTL , AndersonJL , CrandallBG , CutlerM , et al . Dementia and stroke rates were lower among patients receiving long-term anticoagulation therapy with novel oral anticoagulants compared to warfarin. American Journal of Cardiology2015;118(2):210-4. [DOI: 10.1016/j.amjcard.2016.04.039] [PMID: 27236255]">Jacobs 2015</a>; <a href="./references#CD012269-bbs2-0010" title="KwokCS , ShoamaneshA , CopleyHC , MyintPK , LokeYK , BenaventeOR . Efficacy of antiplatelet therapy in secondary prevention following lacunar stroke pooled analysis of randomised trials. Stroke2015;46(4):1014. [DOI: 10.1161/STROKEAHA.114.008422] [PMID: 25721018]">Kwok 2015</a>; <a href="./references#CD012269-bbs2-0015" title="ZhangY , ZhangZ , YangB , LiY , ZhangQ , QuQ , et al. Effects of antiplatelet agents on functional outcome and cognitive status in patients with acute ischaemic stroke. International Journal of Gerontology2014;8(4):189-92. [DOI: 10.1016/j.ijge.2013.12.005]">Zhang 2014</a>), having a mixed population with no or too few participants with cSVD (<a href="./references#CD012269-bbs2-0004" title="WardSA , RanigaP , FerrisNJ , WoodsRL , StoreyE , BaileyMJ , et al. ASPREE-NEURO study protocol: a randomized controlled trial to determine the effect of low-dose aspirin on cerebral microbleeds, white matter hyperintensities, cognition, and stroke in the healthy elderly. International Journal of Stroke2017;12(1):108-13. ">ASPREE‐NEURO</a>; <a href="./references#CD012269-bbs2-0005" title="O'DonnellMJ ,  Eikelboom JW,  Yusuf S,  Diener HC, HartRG , SmithEE , et al. Effect of apixaban on brain infarction and microbleeds: AVERROES – MRI assessment study. American Heart Journal2016;178:145-50. [DOI: 10.1016/j.ahj.2016.03.019]">AVERROES‐MRI assessment study</a>; <a href="./references#CD012269-bbs2-0006" title="SharmaM , HartRG , SmithEE , BoschJ , EikelboomJW , ConnollySJ ,   et al. Rivaroxaban for prevention of covert brain infarcts and cognitive decline: the COMPASS MRI substudy. Stroke2020;51:2901-9. ">COMPASS MRI</a>), or having no outcomes that were relevant to this review (<a href="./references#CD012269-bbs2-0008" title="HanSW ,   LeeS , KimSH , LeeJH ,  KimGS , KimO , et al. Effect of cilostazol in acute lacunar infarction based on pulsatility index of transcranial Doppler (ECLIPse): a multicenter, randomized, double-blind, placebo-controlled trial. European Neurology2013;69:33-40. [DOI: DOI: 10.1159/000338247]">Han 2013</a>; <a href="./references#CD012269-bbs2-0013" title="Shindo-TagawaT , YamasakiY , YoshidaS , KajimotoY , TsujinoT , HakuiN , et al. A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with type II diabetes. Diabetologia2002;45:188-94. ">Shinod‐Tagawa 2002</a>; <a href="./references#CD012269-bbs2-0014" title="XuYY , ZongL , ZhangC , PanY , JingJ , MengX , et al, on behalf of the CHANCE Investigators. The association of white matter hyperintensities with stroke outcomes and antiplatelet therapy in minor stroke patients. Annals of Translational Medicine2020;8:331. [DOI: 10.21037/atm.2020.02.137]">Xu 2020</a>).  </p> </section> </section> <section id="CD012269-sec-0048"> <h3 class="title">Risk of bias in included studies</h3> <p>The quality of included studies was variable. See the risk of bias in the <a href="./references#CD012269-sec-0089" title="">Characteristics of included studies</a> table, <a href="#CD012269-fig-0002">Figure 2</a>, and <a href="#CD012269-fig-0003">Figure 3</a> for full details. </p> <div class="figure" id="CD012269-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012269-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012269.pub2/media/CDSR/CD012269/image_n/nCD012269-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD012269-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="original image" data-id="CD012269-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012269.pub2/media/CDSR/CD012269/image_n/nCD012269-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <section id="CD012269-sec-0049"> <h4 class="title">Allocation</h4> <p>Both <a href="./references#CD012269-bbs2-0003" title="PearceLA , McClureLA , AndersonDC , JacovaC , SharmaM , HartRG , et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurology2014;13:1177-85. [CENTRAL: PMC4284947] [DOI: 10.1016/S1474-4422(14)70224-8]SharmaM , PearceLA , BenaventeOR , AndersonDC , ConnollySJ , PalacioS , et al. Predictors of mortality in patients with lacunar stroke in the Secondary Prevention of Small Subcortical Strokes trial. Stroke; a Journal of Cerebral Circulation2014;45(10):2989–94. [CENTRAL: PMC4175186] [DOI: doi.org/10.1161/STROKEAHA.114.005789] [PMID: 25158772]The SPS3 Investigators, BenaventeOR , CoffeyCS , ConwitR , HartRG , McClureLA , PearceLA , et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. New England Journal of Medicine2012;367(9):817-25. [DOI: 10.1056/NEJMoa1204133]">Pearce SPS3 2014</a> and <a href="./references#CD012269-bbs2-0001" title="JiaJ , WeiC , LiangJ , ZhouA , ZuoX , SongH , et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischaemic small vessel disease: a multicentre, randomised, double-blind, placebo-controlled trial. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2016;12(2):89-99. [DOI: 10.1016/j.jalz.2015.04.010] [PMID: 26086183]">Jia 2016</a> were at low risk of selection bias. We judged <a href="./references#CD012269-bbs2-0002" title="MaestriniI , AltieriM , ClementeLD , VicenziniE , PantanoP , RazE , et al. Longitudinal study on low-dose aspirin versus placebo administration in silent brain infarcts: the SILENCE study. Stroke Research and Treatment2018;2018(7532403):1-9. [DOI: doi.org/10.1155/2018/7532403]">Maestrini SILENCE 2018</a> at unclear risk of bias, as we could not be sure how the possibility to combined randomised and non‐randomised trial design had influenced the allocation of participants. </p> </section> <section id="CD012269-sec-0050"> <h4 class="title">Blinding</h4> <p>We considered <a href="./references#CD012269-bbs2-0001" title="JiaJ , WeiC , LiangJ , ZhouA , ZuoX , SongH , et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischaemic small vessel disease: a multicentre, randomised, double-blind, placebo-controlled trial. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2016;12(2):89-99. [DOI: 10.1016/j.jalz.2015.04.010] [PMID: 26086183]">Jia 2016</a>, <a href="./references#CD012269-bbs2-0002" title="MaestriniI , AltieriM , ClementeLD , VicenziniE , PantanoP , RazE , et al. Longitudinal study on low-dose aspirin versus placebo administration in silent brain infarcts: the SILENCE study. Stroke Research and Treatment2018;2018(7532403):1-9. [DOI: doi.org/10.1155/2018/7532403]">Maestrini SILENCE 2018</a>, and <a href="./references#CD012269-bbs2-0003" title="PearceLA , McClureLA , AndersonDC , JacovaC , SharmaM , HartRG , et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurology2014;13:1177-85. [CENTRAL: PMC4284947] [DOI: 10.1016/S1474-4422(14)70224-8]SharmaM , PearceLA , BenaventeOR , AndersonDC , ConnollySJ , PalacioS , et al. Predictors of mortality in patients with lacunar stroke in the Secondary Prevention of Small Subcortical Strokes trial. Stroke; a Journal of Cerebral Circulation2014;45(10):2989–94. [CENTRAL: PMC4175186] [DOI: doi.org/10.1161/STROKEAHA.114.005789] [PMID: 25158772]The SPS3 Investigators, BenaventeOR , CoffeyCS , ConwitR , HartRG , McClureLA , PearceLA , et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. New England Journal of Medicine2012;367(9):817-25. [DOI: 10.1056/NEJMoa1204133]">Pearce SPS3 2014</a> at low risk of performance and detection bias. Studies were described as double‐blind with matching placebo. Participants, investigators and outcome assessors were masked to the treatment allocation and were unable to preview the randomised assignments. </p> </section> <section id="CD012269-sec-0051"> <h4 class="title">Incomplete outcome data</h4> <p>There was substantial attrition in both <a href="./references#CD012269-bbs2-0002" title="MaestriniI , AltieriM , ClementeLD , VicenziniE , PantanoP , RazE , et al. Longitudinal study on low-dose aspirin versus placebo administration in silent brain infarcts: the SILENCE study. Stroke Research and Treatment2018;2018(7532403):1-9. [DOI: doi.org/10.1155/2018/7532403]">Maestrini SILENCE 2018</a> and <a href="./references#CD012269-bbs2-0003" title="PearceLA , McClureLA , AndersonDC , JacovaC , SharmaM , HartRG , et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurology2014;13:1177-85. [CENTRAL: PMC4284947] [DOI: 10.1016/S1474-4422(14)70224-8]SharmaM , PearceLA , BenaventeOR , AndersonDC , ConnollySJ , PalacioS , et al. Predictors of mortality in patients with lacunar stroke in the Secondary Prevention of Small Subcortical Strokes trial. Stroke; a Journal of Cerebral Circulation2014;45(10):2989–94. [CENTRAL: PMC4175186] [DOI: doi.org/10.1161/STROKEAHA.114.005789] [PMID: 25158772]The SPS3 Investigators, BenaventeOR , CoffeyCS , ConwitR , HartRG , McClureLA , PearceLA , et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. New England Journal of Medicine2012;367(9):817-25. [DOI: 10.1056/NEJMoa1204133]">Pearce SPS3 2014</a>. It is possible that missing follow‐up data could have influenced the outcomes of interest, that is, those with cognitive or functional decline might be more likely to drop out of the full follow‐up period. <a href="./references#CD012269-bbs2-0001" title="JiaJ , WeiC , LiangJ , ZhouA , ZuoX , SongH , et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischaemic small vessel disease: a multicentre, randomised, double-blind, placebo-controlled trial. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2016;12(2):89-99. [DOI: 10.1016/j.jalz.2015.04.010] [PMID: 26086183]">Jia 2016</a> was at low risk of attrition bias. </p> </section> <section id="CD012269-sec-0052"> <h4 class="title">Selective reporting</h4> <p>We judged <a href="./references#CD012269-bbs2-0001" title="JiaJ , WeiC , LiangJ , ZhouA , ZuoX , SongH , et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischaemic small vessel disease: a multicentre, randomised, double-blind, placebo-controlled trial. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2016;12(2):89-99. [DOI: 10.1016/j.jalz.2015.04.010] [PMID: 26086183]">Jia 2016</a> at possible risk of reporting bias, as the protocol was retrospectively registered, the projected sample size did not match the recruitment as proposed by the authors, and several differing outcomes were labelled as "primary outcomes" in their protocol. We also judged <a href="./references#CD012269-bbs2-0002" title="MaestriniI , AltieriM , ClementeLD , VicenziniE , PantanoP , RazE , et al. Longitudinal study on low-dose aspirin versus placebo administration in silent brain infarcts: the SILENCE study. Stroke Research and Treatment2018;2018(7532403):1-9. [DOI: doi.org/10.1155/2018/7532403]">Maestrini SILENCE 2018</a> at possible risk of reporting bias, as the trial was prematurely terminated and the protocol was no longer available on the protocol repository. </p> </section> <section id="CD012269-sec-0053"> <h4 class="title">Other potential sources of bias</h4> <p>The study medication used in <a href="./references#CD012269-bbs2-0001" title="JiaJ , WeiC , LiangJ , ZhouA , ZuoX , SongH , et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischaemic small vessel disease: a multicentre, randomised, double-blind, placebo-controlled trial. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2016;12(2):89-99. [DOI: 10.1016/j.jalz.2015.04.010] [PMID: 26086183]">Jia 2016</a> was donated by Shijiazhuang Pharmaceutical Group Company, but the company was reported as having no other role in the study. The discussion section of <a href="./references#CD012269-bbs2-0001" title="JiaJ , WeiC , LiangJ , ZhouA , ZuoX , SongH , et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischaemic small vessel disease: a multicentre, randomised, double-blind, placebo-controlled trial. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2016;12(2):89-99. [DOI: 10.1016/j.jalz.2015.04.010] [PMID: 26086183]">Jia 2016</a> stated that they had underestimated their sample size due to an overestimation of the drug effect at the clinical trial planning stage. We considered that these two issues posed an unclear risk of other biases. <a href="./references#CD012269-bbs2-0002" title="MaestriniI , AltieriM , ClementeLD , VicenziniE , PantanoP , RazE , et al. Longitudinal study on low-dose aspirin versus placebo administration in silent brain infarcts: the SILENCE study. Stroke Research and Treatment2018;2018(7532403):1-9. [DOI: doi.org/10.1155/2018/7532403]">Maestrini SILENCE 2018</a> and <a href="./references#CD012269-bbs2-0003" title="PearceLA , McClureLA , AndersonDC , JacovaC , SharmaM , HartRG , et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurology2014;13:1177-85. [CENTRAL: PMC4284947] [DOI: 10.1016/S1474-4422(14)70224-8]SharmaM , PearceLA , BenaventeOR , AndersonDC , ConnollySJ , PalacioS , et al. Predictors of mortality in patients with lacunar stroke in the Secondary Prevention of Small Subcortical Strokes trial. Stroke; a Journal of Cerebral Circulation2014;45(10):2989–94. [CENTRAL: PMC4175186] [DOI: doi.org/10.1161/STROKEAHA.114.005789] [PMID: 25158772]The SPS3 Investigators, BenaventeOR , CoffeyCS , ConwitR , HartRG , McClureLA , PearceLA , et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. New England Journal of Medicine2012;367(9):817-25. [DOI: 10.1056/NEJMoa1204133]">Pearce SPS3 2014</a> were at low risk of bias. </p> </section> </section> <section id="CD012269-sec-0054"> <h3 class="title" id="CD012269-sec-0054">Effects of interventions</h3> <p>See: <a href="./full#CD012269-tbl-0001"><b>Summary of findings 1</b> Antiplatelet drug compared to placebo in mixed populations (with or without pre‐existing antiplatelet therapy) for the prevention of cognitive decline and dementia in people with cerebral small vessel disease and no dementia</a>; <a href="./full#CD012269-tbl-0002"><b>Summary of findings 2</b> Antiplatelet therapy compared to placebo for prevention of cognitive decline and dementia in people with cerebral small vessel disease and no dementia</a>; <a href="./full#CD012269-tbl-0003"><b>Summary of findings 3</b> Dual antiplatelet therapy compared to single antiplatelet therapy for prevention of cognitive decline and dementia in people with cerebral small vessel disease and no dementia</a> </p> <p>As the studies differed in their included participants, interventions and outcomes, we decided that a quantitative meta‐analysis was inappropriate. Therefore, we described the three included studies in turn, assessing the strength of evidence at study level, and describing the relevant quantitative data in <a href="#CD012269-tbl-0004">Table 1</a>, <a href="#CD012269-tbl-0005">Table 2</a>, and <a href="#CD012269-tbl-0006">Table 3</a>, and present a narrative summary of the evidence in <a href="#CD012269-sec-0066">Summary of main results</a>.  </p> <div class="table" id="CD012269-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Results of Jia 2016 (efficacy outcomes in intention‐to‐treat population at week 24)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Psychometric scores</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Adjusted mean change from baseline</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Difference in adjusted mean (95% CI)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>DL‐3‐n‐butylphthalide</b> </p> <p><b>(n = 140)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> <p><b>(n = 140)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADAS‐Cog</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−2.46 (SE 0.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.39 (SE 0.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.07 (−2.02 to −0.12)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CIBIC‐plus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.24 (SE 0.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.53 (SE 0.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.29 (−0.48 to −0.10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MMSE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.51 (SE 0.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.26 (SE 0.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26 (−0.25 to 0.76)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.05 (SE 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.02 (SE 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.02 (−0.06 to 0.02)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDR‐SB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.03 (SE 0.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.07 (SE 0.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.04 (−0.16 to 0.24)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.62 (SE 0.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.80 (SE 0.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.18 (−0.70 to 1.07)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.13 (SE 0.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.43 (SE 0.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.29 (−0.15 to 0.74)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Results table extracted from Table 2, <a href="./references#CD012269-bbs2-0001" title="JiaJ , WeiC , LiangJ , ZhouA , ZuoX , SongH , et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischaemic small vessel disease: a multicentre, randomised, double-blind, placebo-controlled trial. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2016;12(2):89-99. [DOI: 10.1016/j.jalz.2015.04.010] [PMID: 26086183]">Jia 2016</a>. The adjustments made to the mean were not clearly stated in the publication.<br/>ADAS‐Cog: 12‐item Alzheimer's Disease Assessment Scale‐Cognitive subscale; ADL: activities of daily living; CDR: Clinical Dementia Rating; CDR‐SB: Clinical Dementia Rating scale Sum of Boxes; CI: confidence interval; CIBIC‐plus: Clinician's Interview‐Based Impression of Change‐Plus Caregiver Input; MMSE: Mini‐Mental State Examination; n: number of participants; NPI: Neuropsychiatric Inventory; SE: standard error. </p> </div> </div> <div class="table" id="CD012269-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Results of SPS3 2014 (mean Cognitive Abilities Screening Instrument (CASI) z‐score over time by assigned antiplatelet treatment)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Time since baseline assessment (years)</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Aspirin + clopidogrel</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Aspirin + placebo</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SD</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1468</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.48</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>974</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>769</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>411</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.60</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Results table extracted from <a href="./references#CD012269-bbs2-0003" title="PearceLA , McClureLA , AndersonDC , JacovaC , SharmaM , HartRG , et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurology2014;13:1177-85. [CENTRAL: PMC4284947] [DOI: 10.1016/S1474-4422(14)70224-8]SharmaM , PearceLA , BenaventeOR , AndersonDC , ConnollySJ , PalacioS , et al. Predictors of mortality in patients with lacunar stroke in the Secondary Prevention of Small Subcortical Strokes trial. Stroke; a Journal of Cerebral Circulation2014;45(10):2989–94. [CENTRAL: PMC4175186] [DOI: doi.org/10.1161/STROKEAHA.114.005789] [PMID: 25158772]The SPS3 Investigators, BenaventeOR , CoffeyCS , ConwitR , HartRG , McClureLA , PearceLA , et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. New England Journal of Medicine2012;367(9):817-25. [DOI: 10.1056/NEJMoa1204133]">Pearce SPS3 2014</a>. Higher score indicates better performance.<br/>n: number of participants; SD: standard deviation. </p> </div> </div> <div class="table" id="CD012269-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Results of SILENCE 2018 (efficacy outcomes of the  randomised participants)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Aspirin</b> </p> <p><b>(n = 24)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> <p><b>(n = 26)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MMSE (median) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29 (IQR 27–30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29 (IQR 27–30) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IADL (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (IQR 8–8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> 8 (IQR 8–8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADL (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (IQR 6–6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (IQR 6–6) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loss to follow‐up (n) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> 8 (33.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (19.2%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events (n)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (8.3%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> 1 (3.8%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in global cognitive score (mean) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.10 (SD 0.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.06 (SD 0.55)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Unpublished data provided by the authors of <a href="./references#CD012269-bbs2-0002" title="MaestriniI , AltieriM , ClementeLD , VicenziniE , PantanoP , RazE , et al. Longitudinal study on low-dose aspirin versus placebo administration in silent brain infarcts: the SILENCE study. Stroke Research and Treatment2018;2018(7532403):1-9. [DOI: doi.org/10.1155/2018/7532403]">Maestrini SILENCE 2018</a>.<br/>ADL: activities of daily living; IADL: Instrumental Activities of Daily Living; IQR: interquartile range; MMSE: Mini‐Mental State Examination; n: number of participants; SD: standard deviation. </p> </div> </div> <section id="CD012269-sec-0055"> <h4 class="title">1. Change in cognitive function from baseline</h4> <p><a href="./references#CD012269-bbs2-0001" title="JiaJ , WeiC , LiangJ , ZhouA , ZuoX , SongH , et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischaemic small vessel disease: a multicentre, randomised, double-blind, placebo-controlled trial. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2016;12(2):89-99. [DOI: 10.1016/j.jalz.2015.04.010] [PMID: 26086183]">Jia 2016</a>: intention‐to‐treat (ITT) analysis involving 280 participants showed a difference in favour of DL‐3‐n‐butylphthalide using the ADAS‐Cog (adjusted MD −1.07, 95% CI −2.02 to −0.12), which equated to an effect size of 0.26 standard deviation. In the per‐protocol analysis, the observed MD was slightly larger at 1.21 points in the same direction. The mean CIBIC‐plus global score also showed a difference in favour of DL‐3‐n‐butylphthalide  (drug‐placebo difference −0.29, 95% CI −0.48 to −0.10, P = 0.003), which equated to an effect size of 0.35 standard deviation. In the per‐protocol analysis, the observed MD was larger at −0.33 points (P &lt; 0.001) in the same direction. There is no consensus on what is a clinically important difference in ADAS‐Cog or CIBIC‐plus for a trial examining cognitive decline, but differences of these magnitudes is unlikely to be of clinical relevance. There were no significant differences for MMSE, CDR global score or CDR‐SB between groups (<a href="#CD012269-tbl-0004">Table 1</a>). We considered this low‐certainty evidence, downgrading twice for indirectness as it is arguable whether DL‐3‐n‐butylphthalide should technically be classified as an antithrombotic therapy and because all participants had cognitive impairment at baseline, and for imprecision. </p> <p><a href="./references#CD012269-bbs2-0002" title="MaestriniI , AltieriM , ClementeLD , VicenziniE , PantanoP , RazE , et al. Longitudinal study on low-dose aspirin versus placebo administration in silent brain infarcts: the SILENCE study. Stroke Research and Treatment2018;2018(7532403):1-9. [DOI: doi.org/10.1155/2018/7532403]">Maestrini SILENCE 2018</a> described various cognitive tests. There was no evidence of a difference between the aspirin and placebo groups in change in cognition, measured with a neuropsychological test battery, or in MMSE scores at the end of follow‐up (<a href="#CD012269-tbl-0006">Table 3</a>). We considered this very low‐certainty evidence, downgrading for risk of bias, indirectness and imprecision.  </p> <p><a href="./references#CD012269-bbs2-0003" title="PearceLA , McClureLA , AndersonDC , JacovaC , SharmaM , HartRG , et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurology2014;13:1177-85. [CENTRAL: PMC4284947] [DOI: 10.1016/S1474-4422(14)70224-8]SharmaM , PearceLA , BenaventeOR , AndersonDC , ConnollySJ , PalacioS , et al. Predictors of mortality in patients with lacunar stroke in the Secondary Prevention of Small Subcortical Strokes trial. Stroke; a Journal of Cerebral Circulation2014;45(10):2989–94. [CENTRAL: PMC4175186] [DOI: doi.org/10.1161/STROKEAHA.114.005789] [PMID: 25158772]The SPS3 Investigators, BenaventeOR , CoffeyCS , ConwitR , HartRG , McClureLA , PearceLA , et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. New England Journal of Medicine2012;367(9):817-25. [DOI: 10.1056/NEJMoa1204133]">Pearce SPS3 2014</a>: there was improvement in the CASI z‐score from baseline to each of the years one to five in both the aspirin plus clopidogrel and placebo groups, but the study reported that only the improvement from study entry to year one was statistically significant (MD 0.11, SD 0.84, P &lt; 0.0001). The CASI z‐scores were not different between the two treatment groups over time (P = 0.858) (<a href="./references#CD012269-bbs2-0003" title="PearceLA , McClureLA , AndersonDC , JacovaC , SharmaM , HartRG , et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurology2014;13:1177-85. [CENTRAL: PMC4284947] [DOI: 10.1016/S1474-4422(14)70224-8]SharmaM , PearceLA , BenaventeOR , AndersonDC , ConnollySJ , PalacioS , et al. Predictors of mortality in patients with lacunar stroke in the Secondary Prevention of Small Subcortical Strokes trial. Stroke; a Journal of Cerebral Circulation2014;45(10):2989–94. [CENTRAL: PMC4175186] [DOI: doi.org/10.1161/STROKEAHA.114.005789] [PMID: 25158772]The SPS3 Investigators, BenaventeOR , CoffeyCS , ConwitR , HartRG , McClureLA , PearceLA , et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. New England Journal of Medicine2012;367(9):817-25. [DOI: 10.1056/NEJMoa1204133]">Pearce SPS3 2014</a>). We considered this low‐certainty evidence, downgrading for indirectness as most participants had MCI at baseline, making it difficult to translate these findings to the general small‐vessel disease population, and for imprecision. </p> </section> <section id="CD012269-sec-0056"> <h4 class="title">2. Incident dementia</h4> <p>No studies reported incident dementia. </p> </section> <section id="CD012269-sec-0057"> <h4 class="title">3. Major bleeding events (intracranial and extracranial)</h4> <p><a href="./references#CD012269-bbs2-0001" title="JiaJ , WeiC , LiangJ , ZhouA , ZuoX , SongH , et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischaemic small vessel disease: a multicentre, randomised, double-blind, placebo-controlled trial. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2016;12(2):89-99. [DOI: 10.1016/j.jalz.2015.04.010] [PMID: 26086183]">Jia 2016</a> reported two intracranial haemorrhagic events, one in each group (0.7% with DL‐3‐n‐butylphthalide group versus 0.7% with placebo; P = 1.00). We considered this very low‐certainty evidence, downgrading it twice for indirectness as it is arguable whether DL‐3‐n‐butylphthalide should technically be classified as an antithrombotic therapy and because most participants had cognitive impairment at baseline, and once for imprecision because only one study contributed to this finding. The study did not report extracranial haemorrhage.  </p> <p><a href="./references#CD012269-bbs2-0002" title="MaestriniI , AltieriM , ClementeLD , VicenziniE , PantanoP , RazE , et al. Longitudinal study on low-dose aspirin versus placebo administration in silent brain infarcts: the SILENCE study. Stroke Research and Treatment2018;2018(7532403):1-9. [DOI: doi.org/10.1155/2018/7532403]">Maestrini SILENCE 2018</a> did not report major bleeding events. They reported fatal and non‐fatal stroke rates, but these are not categorised as ischaemic or haemorrhagic. There were gastrointestinal adverse events, but it was unclear whether these related to bleeding.  </p> <p><a href="./references#CD012269-bbs2-0003" title="PearceLA , McClureLA , AndersonDC , JacovaC , SharmaM , HartRG , et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurology2014;13:1177-85. [CENTRAL: PMC4284947] [DOI: 10.1016/S1474-4422(14)70224-8]SharmaM , PearceLA , BenaventeOR , AndersonDC , ConnollySJ , PalacioS , et al. Predictors of mortality in patients with lacunar stroke in the Secondary Prevention of Small Subcortical Strokes trial. Stroke; a Journal of Cerebral Circulation2014;45(10):2989–94. [CENTRAL: PMC4175186] [DOI: doi.org/10.1161/STROKEAHA.114.005789] [PMID: 25158772]The SPS3 Investigators, BenaventeOR , CoffeyCS , ConwitR , HartRG , McClureLA , PearceLA , et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. New England Journal of Medicine2012;367(9):817-25. [DOI: 10.1056/NEJMoa1204133]">Pearce SPS3 2014</a> reported both intracranial and extracranial haemorrhagic events. The overall risk of major haemorrhage was almost doubled with dual antiplatelet therapy (105 haemorrhages, 2.1% per year) compared with aspirin alone (56 haemorrhages, 1.1% per year) (HR 1.97, 95% CI 1.41 to 2.71; P &lt; 0.001). Intracranial haemorrhagic events occurred in 15 participants assigned to aspirin and 22 participants assigned to aspirin plus clopidogrel (HR 1.52, 95% CI 0.79 to 2.93; P = 0.21). Extracranial haemorrhagic events occurred in 42 participants assigned to aspirin and 87 assigned to aspirin plus clopidogrel (HR 2.15, 95% CI 1.49 to 3.11; P &lt; 0.001); 28 of these bleedings were gastrointestinal in the aspirin group and 58 in the aspirin plus clopidogrel group (HR 2.14, 95% CI 1.36 to 3.36; P &lt; 0.001). There were four fatal haemorrhagic events in the aspirin group and nine in the aspirin plus clopidogrel group (HR 2.29, 95% CI 0.7 to 7.42; P = 0.17). All four fatal haemorrhages in the aspirin group were intracranial haemorrhage versus seven fatal intracranial haemorrhages in the aspirin plus clopidogrel group (HR 1.78, 95% CI 0.52 to 6.07; P = 0.36). The remaining two fatal haemorrhagic events in the aspirin plus clopidogrel group were extracranial. We considered this low‐certainty evidence, downgrading once for indirectness because most participants had MCI at baseline and once for imprecision because only one study contributed to this finding. </p> </section> <section id="CD012269-sec-0058"> <h4 class="title">4. Functional outcome (activities of daily living)</h4> <p><a href="./references#CD012269-bbs2-0001" title="JiaJ , WeiC , LiangJ , ZhouA , ZuoX , SongH , et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischaemic small vessel disease: a multicentre, randomised, double-blind, placebo-controlled trial. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2016;12(2):89-99. [DOI: 10.1016/j.jalz.2015.04.010] [PMID: 26086183]">Jia 2016</a>: there was no evidence of a difference in ADL between DL‐3‐n‐butylphthalide and placebo groups (adjusted MD 0.18, 95% CI −0.70 to 1.07). It was unclear what the minimum clinically important difference would be for the ADL scale employed as it is not a commonly used measure. We considered this very low‐certainty evidence, downgrading twice for indirectness and once for imprecision. </p> <p><a href="./references#CD012269-bbs2-0002" title="MaestriniI , AltieriM , ClementeLD , VicenziniE , PantanoP , RazE , et al. Longitudinal study on low-dose aspirin versus placebo administration in silent brain infarcts: the SILENCE study. Stroke Research and Treatment2018;2018(7532403):1-9. [DOI: doi.org/10.1155/2018/7532403]">Maestrini SILENCE 2018</a>: there was no evidence of a difference in ADL between aspirin and placebo (<a href="#CD012269-tbl-0006">Table 3</a>). The ADL scale employed was not described. We considered this to be very low certainty evidence, downgrading it for risk of bias, indirectness and imprecision.  </p> <p><a href="./references#CD012269-bbs2-0003" title="PearceLA , McClureLA , AndersonDC , JacovaC , SharmaM , HartRG , et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurology2014;13:1177-85. [CENTRAL: PMC4284947] [DOI: 10.1016/S1474-4422(14)70224-8]SharmaM , PearceLA , BenaventeOR , AndersonDC , ConnollySJ , PalacioS , et al. Predictors of mortality in patients with lacunar stroke in the Secondary Prevention of Small Subcortical Strokes trial. Stroke; a Journal of Cerebral Circulation2014;45(10):2989–94. [CENTRAL: PMC4175186] [DOI: doi.org/10.1161/STROKEAHA.114.005789] [PMID: 25158772]The SPS3 Investigators, BenaventeOR , CoffeyCS , ConwitR , HartRG , McClureLA , PearceLA , et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. New England Journal of Medicine2012;367(9):817-25. [DOI: 10.1056/NEJMoa1204133]">Pearce SPS3 2014</a> did not report functional outcome. </p> </section> <section id="CD012269-sec-0059"> <h4 class="title">5. Incident ischaemic stroke or transient ischaemic attack</h4> <p><a href="./references#CD012269-bbs2-0001" title="JiaJ , WeiC , LiangJ , ZhouA , ZuoX , SongH , et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischaemic small vessel disease: a multicentre, randomised, double-blind, placebo-controlled trial. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2016;12(2):89-99. [DOI: 10.1016/j.jalz.2015.04.010] [PMID: 26086183]">Jia 2016</a>: reported five participants who experienced new ischaemic stroke: two  (1.4%) in the DL‐3‐n‐butylphthalide group and three  (2.1%) in the placebo group (P = 1.00). There was one TIA (0.7%) in the DL‐3‐n‐butylphthalide group versus none in the placebo group. We considered this very low‐certainty evidence, downgrading twice for indirectness and once for imprecision. </p> <p><a href="./references#CD012269-bbs2-0002" title="MaestriniI , AltieriM , ClementeLD , VicenziniE , PantanoP , RazE , et al. Longitudinal study on low-dose aspirin versus placebo administration in silent brain infarcts: the SILENCE study. Stroke Research and Treatment2018;2018(7532403):1-9. [DOI: doi.org/10.1155/2018/7532403]">Maestrini SILENCE 2018</a> reported clinical stroke and TIA with no difference between groups. In the aspirin group, there was one stroke event (3%) and no TIA, while in the placebo group there were two strokes (4%) and two TIAs (2%). We considered this very low‐certainty evidence, downgrading once each for risk of bias, indirectness and imprecision. </p> <p><a href="./references#CD012269-bbs2-0003" title="PearceLA , McClureLA , AndersonDC , JacovaC , SharmaM , HartRG , et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurology2014;13:1177-85. [CENTRAL: PMC4284947] [DOI: 10.1016/S1474-4422(14)70224-8]SharmaM , PearceLA , BenaventeOR , AndersonDC , ConnollySJ , PalacioS , et al. Predictors of mortality in patients with lacunar stroke in the Secondary Prevention of Small Subcortical Strokes trial. Stroke; a Journal of Cerebral Circulation2014;45(10):2989–94. [CENTRAL: PMC4175186] [DOI: doi.org/10.1161/STROKEAHA.114.005789] [PMID: 25158772]The SPS3 Investigators, BenaventeOR , CoffeyCS , ConwitR , HartRG , McClureLA , PearceLA , et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. New England Journal of Medicine2012;367(9):817-25. [DOI: 10.1056/NEJMoa1204133]">Pearce SPS3 2014</a> reported both ischaemic stroke and TIA. In total, 124 participants in the aspirin group versus 100 participants in the aspirin plus clopidogrel group had ischaemic stroke (HR 0.82, 95% CI 0.63 to 1.09; P = 0.13); while 39 participants in the aspirin group versus 28 in the aspirin plus clopidogrel group had TIA (HR 0.73, 95% CI 0.45 to 1.18; P = 0.19). We considered this low‐certainty evidence, downgrading once for indirectness and once for imprecision.  </p> </section> <section id="CD012269-sec-0060"> <h4 class="title">6. Death</h4> <p><a href="./references#CD012269-bbs2-0001" title="JiaJ , WeiC , LiangJ , ZhouA , ZuoX , SongH , et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischaemic small vessel disease: a multicentre, randomised, double-blind, placebo-controlled trial. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2016;12(2):89-99. [DOI: 10.1016/j.jalz.2015.04.010] [PMID: 26086183]">Jia 2016</a> reported four participants who died during the study: two (1.5%) in the DL‐3‐n‐butylphthalide group and two (1.5%) in the place group (P = 1.00). </p> <p><a href="./references#CD012269-bbs2-0002" title="MaestriniI , AltieriM , ClementeLD , VicenziniE , PantanoP , RazE , et al. Longitudinal study on low-dose aspirin versus placebo administration in silent brain infarcts: the SILENCE study. Stroke Research and Treatment2018;2018(7532403):1-9. [DOI: doi.org/10.1155/2018/7532403]">Maestrini SILENCE 2018</a> reported two (6%) cases of fatal myocardial infarction in the aspirin group and one (2%) event of fatal myocardial infarction in the placebo group. There were no other deaths reported.  </p> <p><a href="./references#CD012269-bbs2-0003" title="PearceLA , McClureLA , AndersonDC , JacovaC , SharmaM , HartRG , et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurology2014;13:1177-85. [CENTRAL: PMC4284947] [DOI: 10.1016/S1474-4422(14)70224-8]SharmaM , PearceLA , BenaventeOR , AndersonDC , ConnollySJ , PalacioS , et al. Predictors of mortality in patients with lacunar stroke in the Secondary Prevention of Small Subcortical Strokes trial. Stroke; a Journal of Cerebral Circulation2014;45(10):2989–94. [CENTRAL: PMC4175186] [DOI: doi.org/10.1161/STROKEAHA.114.005789] [PMID: 25158772]The SPS3 Investigators, BenaventeOR , CoffeyCS , ConwitR , HartRG , McClureLA , PearceLA , et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. New England Journal of Medicine2012;367(9):817-25. [DOI: 10.1056/NEJMoa1204133]">Pearce SPS3 2014</a> reported 78 deaths in the aspirin group versus 113 deaths in the aspirin plus clopidogrel group (HR 1.5, 95% CI 1.1 to 2.0; P = 0.004). There were four fatal haemorrhagic events in the aspirin group and nine fatal haemorrhage events in the aspirin plus clopidogrel group (HR 2.29, 95% CI 0.7 to 7.42; P = 0.17).  </p> </section> <section id="CD012269-sec-0061"> <h4 class="title">7. Any adverse events (excluding bleeding)</h4> <p><a href="./references#CD012269-bbs2-0001" title="JiaJ , WeiC , LiangJ , ZhouA , ZuoX , SongH , et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischaemic small vessel disease: a multicentre, randomised, double-blind, placebo-controlled trial. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2016;12(2):89-99. [DOI: 10.1016/j.jalz.2015.04.010] [PMID: 26086183]">Jia 2016</a>: adverse events were mostly mild to moderate in severity. The overall adverse event rate was 21% in the DL‐3‐n‐butylphthalide group versus 14% in the placebo group (P = 0.08). Adverse events were deemed possibly or probably related to the study drug in nine participants: five (3.6%) in the DL‐3‐n‐butylphthalide group and four (2.9%) in the placebo group (P = 1.00). We considered this very low‐certainty evidence, downgrading twice for indirectness and once for imprecision. </p> <p><a href="./references#CD012269-bbs2-0002" title="MaestriniI , AltieriM , ClementeLD , VicenziniE , PantanoP , RazE , et al. Longitudinal study on low-dose aspirin versus placebo administration in silent brain infarcts: the SILENCE study. Stroke Research and Treatment2018;2018(7532403):1-9. [DOI: doi.org/10.1155/2018/7532403]">Maestrini SILENCE 2018</a> reported any adverse event, including two events (8.3%) in the aspirin group and one event (3.8%) in the placebo group. We considered this very low‐certainty evidence, downgrading once each for risk of bias, indirectness and imprecision.  </p> <p><a href="./references#CD012269-bbs2-0003" title="PearceLA , McClureLA , AndersonDC , JacovaC , SharmaM , HartRG , et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurology2014;13:1177-85. [CENTRAL: PMC4284947] [DOI: 10.1016/S1474-4422(14)70224-8]SharmaM , PearceLA , BenaventeOR , AndersonDC , ConnollySJ , PalacioS , et al. Predictors of mortality in patients with lacunar stroke in the Secondary Prevention of Small Subcortical Strokes trial. Stroke; a Journal of Cerebral Circulation2014;45(10):2989–94. [CENTRAL: PMC4175186] [DOI: doi.org/10.1161/STROKEAHA.114.005789] [PMID: 25158772]The SPS3 Investigators, BenaventeOR , CoffeyCS , ConwitR , HartRG , McClureLA , PearceLA , et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. New England Journal of Medicine2012;367(9):817-25. [DOI: 10.1056/NEJMoa1204133]">Pearce SPS3 2014</a> did not report any adverse event (excluding bleeding).  </p> </section> <section id="CD012269-sec-0062"> <h4 class="title">8. Withdrawal from the allocated treatment (excluding death)</h4> <p><a href="./references#CD012269-bbs2-0001" title="JiaJ , WeiC , LiangJ , ZhouA , ZuoX , SongH , et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischaemic small vessel disease: a multicentre, randomised, double-blind, placebo-controlled trial. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2016;12(2):89-99. [DOI: 10.1016/j.jalz.2015.04.010] [PMID: 26086183]">Jia 2016</a> reported 33/280 participants discontinued the allocated treatment: seven participants withdrew consent (four from the DL‐3‐n‐butylphthalide group versus three from the placebo group); 18 participants were lost to follow‐up (10 from the DL‐3‐n‐butylphthalide group versus eight from the placebo group); three participants withdrew from the treatment due to possibly drug‐related gastrointestinal reactions (all from the DL‐3‐n‐butylphthalide group); and five participants withdrew due to worsened comorbidities (four from the DL‐3‐n‐butylphthalide group versus one from the placebo group). The OR for withdrawal from treatment was 1.88 favouring placebo (95% CI 0.90 to 3.42). We considered this very low‐certainty evidence, downgrading twice for indirectness and once for imprecision. </p> <p><a href="./references#CD012269-bbs2-0002" title="MaestriniI , AltieriM , ClementeLD , VicenziniE , PantanoP , RazE , et al. Longitudinal study on low-dose aspirin versus placebo administration in silent brain infarcts: the SILENCE study. Stroke Research and Treatment2018;2018(7532403):1-9. [DOI: doi.org/10.1155/2018/7532403]">Maestrini SILENCE 2018</a> reported numbers completing follow‐up as 16 (66.7%) in the aspirin group and 21 (80.8%) in the control group. We considered this very low‐certainty evidence, downgrading once each for risk of bias, indirectness and imprecision.  </p> <p><a href="./references#CD012269-bbs2-0003" title="PearceLA , McClureLA , AndersonDC , JacovaC , SharmaM , HartRG , et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurology2014;13:1177-85. [CENTRAL: PMC4284947] [DOI: 10.1016/S1474-4422(14)70224-8]SharmaM , PearceLA , BenaventeOR , AndersonDC , ConnollySJ , PalacioS , et al. Predictors of mortality in patients with lacunar stroke in the Secondary Prevention of Small Subcortical Strokes trial. Stroke; a Journal of Cerebral Circulation2014;45(10):2989–94. [CENTRAL: PMC4175186] [DOI: doi.org/10.1161/STROKEAHA.114.005789] [PMID: 25158772]The SPS3 Investigators, BenaventeOR , CoffeyCS , ConwitR , HartRG , McClureLA , PearceLA , et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. New England Journal of Medicine2012;367(9):817-25. [DOI: 10.1056/NEJMoa1204133]">Pearce SPS3 2014</a> reported mean rate of adherence to the assigned antiplatelet regimen was 94%. Permanent discontinuation of the assigned antiplatelet therapy occurred in 30% of participants receiving aspirin plus clopidogrel and 27% of those receiving aspirin (P = 0.02). We considered this low‐certainty evidence, downgrading once for indirectness and once for imprecision.  </p> </section> <section id="CD012269-sec-0063"> <h4 class="title">9. New cerebral microbleeds on neuroimaging</h4> <p>No trial reported new cerebral microbleeds on neuroimaging.</p> </section> <section id="CD012269-sec-0064"> <h4 class="title">10. Incident mild cognitive impairment</h4> <p><a href="./references#CD012269-bbs2-0001" title="JiaJ , WeiC , LiangJ , ZhouA , ZuoX , SongH , et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischaemic small vessel disease: a multicentre, randomised, double-blind, placebo-controlled trial. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2016;12(2):89-99. [DOI: 10.1016/j.jalz.2015.04.010] [PMID: 26086183]">Jia 2016</a>: not applicable as all participants had cognitive impairment at baseline. </p> <p><a href="./references#CD012269-bbs2-0002" title="MaestriniI , AltieriM , ClementeLD , VicenziniE , PantanoP , RazE , et al. Longitudinal study on low-dose aspirin versus placebo administration in silent brain infarcts: the SILENCE study. Stroke Research and Treatment2018;2018(7532403):1-9. [DOI: doi.org/10.1155/2018/7532403]">Maestrini SILENCE 2018</a> did not report incident MCI.  </p> <p><a href="./references#CD012269-bbs2-0003" title="PearceLA , McClureLA , AndersonDC , JacovaC , SharmaM , HartRG , et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurology2014;13:1177-85. [CENTRAL: PMC4284947] [DOI: 10.1016/S1474-4422(14)70224-8]SharmaM , PearceLA , BenaventeOR , AndersonDC , ConnollySJ , PalacioS , et al. Predictors of mortality in patients with lacunar stroke in the Secondary Prevention of Small Subcortical Strokes trial. Stroke; a Journal of Cerebral Circulation2014;45(10):2989–94. [CENTRAL: PMC4175186] [DOI: doi.org/10.1161/STROKEAHA.114.005789] [PMID: 25158772]The SPS3 Investigators, BenaventeOR , CoffeyCS , ConwitR , HartRG , McClureLA , PearceLA , et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. New England Journal of Medicine2012;367(9):817-25. [DOI: 10.1056/NEJMoa1204133]">Pearce SPS3 2014</a> reported the incidence of MCI. At study entry, 1303 (45%) participants already fulfilled a diagnosis of MCI. Of the remaining 1413 participants without MCI at study entry, 376 (27%) participants developed MCI and there was no difference between groups (annual incidence 9.7% (189 events in 721 participants over a mean of 2.7 years of follow‐up) in the aspirin plus clopidogrel group versus 9.9% (187 events in 692 participants over a mean of 2.7 years of follow‐up) in the aspirin plus placebo group (P = 0.704). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012269-sec-0065" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012269-sec-0065"></div> <p>The three included trials were too heterogeneous to allow quantitative meta‐analysis. We described each study as a narrative with corresponding tables describing the study results. </p> <section id="CD012269-sec-0066"> <h3 class="title" id="CD012269-sec-0066">Summary of main results</h3> <p>We identified three studies that included 3384 participants in total and assessed the effects of antithrombotic therapy for the prevention of cognitive decline in people with cSVD on neuroimaging but without dementia  (<a href="./references#CD012269-bbs2-0001" title="JiaJ , WeiC , LiangJ , ZhouA , ZuoX , SongH , et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischaemic small vessel disease: a multicentre, randomised, double-blind, placebo-controlled trial. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2016;12(2):89-99. [DOI: 10.1016/j.jalz.2015.04.010] [PMID: 26086183]">Jia 2016</a>; <a href="./references#CD012269-bbs2-0002" title="MaestriniI , AltieriM , ClementeLD , VicenziniE , PantanoP , RazE , et al. Longitudinal study on low-dose aspirin versus placebo administration in silent brain infarcts: the SILENCE study. Stroke Research and Treatment2018;2018(7532403):1-9. [DOI: doi.org/10.1155/2018/7532403]">Maestrini SILENCE 2018</a>; <a href="./references#CD012269-bbs2-0003" title="PearceLA , McClureLA , AndersonDC , JacovaC , SharmaM , HartRG , et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurology2014;13:1177-85. [CENTRAL: PMC4284947] [DOI: 10.1016/S1474-4422(14)70224-8]SharmaM , PearceLA , BenaventeOR , AndersonDC , ConnollySJ , PalacioS , et al. Predictors of mortality in patients with lacunar stroke in the Secondary Prevention of Small Subcortical Strokes trial. Stroke; a Journal of Cerebral Circulation2014;45(10):2989–94. [CENTRAL: PMC4175186] [DOI: doi.org/10.1161/STROKEAHA.114.005789] [PMID: 25158772]The SPS3 Investigators, BenaventeOR , CoffeyCS , ConwitR , HartRG , McClureLA , PearceLA , et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. New England Journal of Medicine2012;367(9):817-25. [DOI: 10.1056/NEJMoa1204133]">Pearce SPS3 2014</a>).  </p> <p>There was considerable heterogeneity across the studies in terms of population assessed, antithrombotic strategy studied and outcomes described. We considered it inappropriate to create quantitative summary estimates using these three very different studies. However, there were consistent findings across many of the outcomes of interest and this allowed us to offer a class effect summary of the evidence for a potent versus less potent antithrombotic approach in people living with cSVD. </p> <p>Across the various measures of general cognition, incident cognitive syndromes (i.e. dementia and MCI) and ADL, there was no convincing evidence of a beneficial effect of antithrombotic therapy in addition to usual care. The single study that reported some potential improvement in cognitive function found inconsistent results with some cognitive outcomes suggesting benefit and others suggesting no effect. Even if we consider the positive cognitive outcomes from this trial in isolation, the size of effect was probably less than would be considered clinically meaningful. Based on the evidence from all three included studies, there is little support for a strategy of routinely using antithrombotic therapy to prevent cognitive decline associated with cSVD. </p> <p>A signal of potential harm was suggested in the outcomes of bleeding (both intracranial and extracranial), adverse events and treatment discontinuation. This is a reminder that antithrombotic therapy is not a completely benign intervention and can be associated with risks of harm. However, there was also a signal, albeit not statistically significant, that a more potent antithrombotic strategy may reduce the risk of stroke, which is a common complication of cSVD. Recurrent stroke is a powerful risk factor for cognitive decline, so if antithrombotic therapy can reduce stroke incidence then, in theory at least, they could indirectly reduce the cognitive effects of further cerebrovascular events. </p> </section> <section id="CD012269-sec-0067"> <h3 class="title" id="CD012269-sec-0067">Overall completeness and applicability of evidence</h3> <p>The process of conducting this review highlighted general issues with research in the field of small vessel disease. </p> <p>The first issue was with the definition of the population. Our interest was people who had neuroimaging markers of cSVD, but no evidence of dementia. We based our definition of neuroimaging cSVD on the STRIVE criteria where possible but majored on white matter disease and covert stroke lesions. Increasingly, other brain imaging lesions associated cSVD are recognised and these may serve as better biomarkers of cerebrovascular cognitive problems, for example enlarged perivascular spaces and certain patterns of atrophy (<a href="./references#CD012269-bbs2-0026" title="ArbaF , QuinnTJ , HankeyGJ , LeesKR , WardlawJM , AliM , et al. Enlarged perivascular spaces and cognitive impairment after stroke and transient ischemic attack. International Journal of Stroke2018;13:47-56. [DOI: 10.1177/1747493016666091]">Arba 2018</a>). </p> <p>Our operationalisation of the neuroimaging of cSVD included any person with lacunar stroke. Baseline neuroimaging is mandated in stroke trials of antithrombotic therapy to exclude intracerebral haemorrhage. So, potentially any stroke trial of antithrombotic therapy that included cognitive outcomes could be eligible for our review. To ensure we did not miss relevant information, we complemented our primary search of the literature, which used a search strategy designed around cSVD and vascular cognitive impairment, with a second focussed search of all the antithrombotic therapy trials held within the Cochrane Stroke Group database. We found several studies that could have contributed data to our review if the results were presented for a subgroup restricted to lacunar stroke. Such subgroup analyses were not available in the primary studies and results were only presented in an aggregate format for all ischaemic stroke types. Requests to authors to share these data did not return data that we could have used. </p> <p>Another issue with the population was around defining a minimum degree of cSVD change. Study populations with baseline neuroimaging were often mixed, with some participants showing evidence of a spectrum of cSVD and others showing none of the common features. We had to set a threshold for the proportion of baseline cSVD that we would accept and in doing so we had to exclude certain studies that could have been relevant to the broader question around antithrombotic therapy and progression of radiological and clinical features of cSVD. At the individual level, there are many markers of cSVD and these tend to increase with increasing age. There is then the issue of when are small vessel changes 'acceptable for age' and when do they become 'pathological'. There is no consensus on this issue, and many believe that all 'age‐related changes' are pathological, although there have been attempts to offer age‐related normative values (<a href="./references#CD012269-bbs2-0060" title="SmithEE , SaposnikG , BiesselsGJ , DoubalFN , FornageM , GorelickPB , et al, American Heart Association Stroke Council, Council on Cardiovascular Radiology and Intervention, Council on Functional Genomics and Translational Biology, and Council on Hypertension. Prevention of stroke in patients with silent cerebrovascular disease: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke2017;48(6):e44-e71. [DOI: doi.org/10.1161/STR.0000000000000116]">Smith 2017</a>). Again, we had to set a threshold of a minimum of at least 'mild' cSVD, but we recognise that this is an arbitrary threshold with no agreed definition, and through this categorisation we may have excluded certain studies that could have been relevant to the broader issue of antithrombotic therapy and cognitive decline.  Furthermore, we included both participants with recent lacunar infarctions (<a href="./references#CD012269-bbs2-0003" title="PearceLA , McClureLA , AndersonDC , JacovaC , SharmaM , HartRG , et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurology2014;13:1177-85. [CENTRAL: PMC4284947] [DOI: 10.1016/S1474-4422(14)70224-8]SharmaM , PearceLA , BenaventeOR , AndersonDC , ConnollySJ , PalacioS , et al. Predictors of mortality in patients with lacunar stroke in the Secondary Prevention of Small Subcortical Strokes trial. Stroke; a Journal of Cerebral Circulation2014;45(10):2989–94. [CENTRAL: PMC4175186] [DOI: doi.org/10.1161/STROKEAHA.114.005789] [PMID: 25158772]The SPS3 Investigators, BenaventeOR , CoffeyCS , ConwitR , HartRG , McClureLA , PearceLA , et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. New England Journal of Medicine2012;367(9):817-25. [DOI: 10.1056/NEJMoa1204133]">Pearce SPS3 2014</a>) and with more chronic forms of SVD (<a href="./references#CD012269-bbs2-0001" title="JiaJ , WeiC , LiangJ , ZhouA , ZuoX , SongH , et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischaemic small vessel disease: a multicentre, randomised, double-blind, placebo-controlled trial. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2016;12(2):89-99. [DOI: 10.1016/j.jalz.2015.04.010] [PMID: 26086183]">Jia 2016</a>; <a href="./references#CD012269-bbs2-0002" title="MaestriniI , AltieriM , ClementeLD , VicenziniE , PantanoP , RazE , et al. Longitudinal study on low-dose aspirin versus placebo administration in silent brain infarcts: the SILENCE study. Stroke Research and Treatment2018;2018(7532403):1-9. [DOI: doi.org/10.1155/2018/7532403]">Maestrini SILENCE 2018</a>). These populations are probably slightly different in risk profiles and secondary prevention, potentially mitigating the effect of the intervention. For our included studies, there was no effect of the intervention both for populations with acute and more chronic SVD. </p> <p>As there are several antithrombotic agents used in vascular medicine, we were deliberately inclusive. All the included trials were of antiplatelet agents, with no eligible studies describing the effects of anticoagulants. Within the review remit, we included differing potency of drugs or combinations with one study assessing low‐dose aspirin, one study comparing dual antiplatelet therapy versus single antiplatelet therapy, and one study of a compound (DL‐3‐n‐butylphthalide) that some might argue does not primarily belong within the antithrombotic drug class. </p> <p>Given the differing contexts of the studies, the comparator also differed between the studies and usual care could have included the routine use of an antithrombotic agent, for example in participants who were included on the basis of lacunar stroke. Thus, while our initial interest was the effect of antithrombotic compared to no antithrombotic, for many of the participants included in eligible studies the data described additional versus single antithrombotic. </p> <p>The intervention and follow‐up durations were different between included studies (varying from 24 weeks to four years of intervention and six months to four years of follow‐up). Trials investigating preventive strategies for cognitive decline and dementia require long‐term surveillance of participants due to the slow progression and low incidence of the condition under study (<a href="./references#CD012269-bbs2-0056" title="RichardE , AndrieuS , SolomonA , MangialascheF , AhtiluotoS , Moll van CharanteEP , et al. Methodological challenges in designing dementia prevention trials – the European Dementia Prevention Initiative (EDPI). Journal of Neurological Sciences2012;322(1):64-70.">Richard 2012</a>). Similarly, trials with a short intervention duration might pick up changes in cognition that are not sustainable over time (<a href="./references#CD012269-bbs2-0029" title="BeishuizenCR , StephanBC , vanGoolWA , BrayneC , PetersRJ , AndrieuS , et al. Web-based interventions targeting cardiovascular risk factors in middle-aged and older people: a systematic review and meta-analysis. Journal of Medical Internet Research2016;18(3):e55.">Beishuizen 2016</a>). Therefore, some caution is warranted when interpreting findings from studies with a relatively short intervention or follow‐up (or both) duration. Future trials should aim for long‐term follow‐up of cognitive decline or dementia and could potentially consider adding surrogate markers for cognitive decline and dementia (e.g. imaging markers or simple clinical (memory) test) as an interim outcome. </p> <p>The decision to study a population free of dementia at baseline was taken because we anticipated that progression to frank dementia would be an important clinical outcome of relevant trials. In fact no trials reported useable data on incident dementia, although one study described incident MCI. Moreover, one study did not report how (or if) they formally excluded dementia, though this is highly likely as participants were able to give informed consent. Rather, the included studies reported a heterogeneous mix of cognitive assessment tools. This inconsistency in cognitive assessment methods is common to both dementia and stroke research.  </p> <p>The natural history and management of lacunar stroke, early‐stage vascular cognitive impairment and incidentally detected neuroimaging features of cSVD are very different. In retrospect, and for future studies, it may have been more useful to distinguish 'silent' or 'covert' cSVD (with no clinical stroke and no frank cognitive syndrome) from 'clinically apparent' cSVD presenting with a stroke. </p> </section> <section id="CD012269-sec-0068"> <h3 class="title" id="CD012269-sec-0068">Quality of the evidence</h3> <p>We could not perform meta‐analysis as the included trials were heterogeneous. Many of our prespecified key outcomes were not reported in the included trials, for example, no trial reported incident dementia. Moreover, the observed evidence was of very low to low certainty, meaning  our confidence in the reported effect estimates is limited. The certainty of our evidence was compromised by several factors. Risk of bias was a major issue for one trial (<a href="./references#CD012269-bbs2-0002" title="MaestriniI , AltieriM , ClementeLD , VicenziniE , PantanoP , RazE , et al. Longitudinal study on low-dose aspirin versus placebo administration in silent brain infarcts: the SILENCE study. Stroke Research and Treatment2018;2018(7532403):1-9. [DOI: doi.org/10.1155/2018/7532403]">Maestrini SILENCE 2018</a>), while applicability to the study question was also an issue. Of the remaining trials, <a href="./references#CD012269-bbs2-0003" title="PearceLA , McClureLA , AndersonDC , JacovaC , SharmaM , HartRG , et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurology2014;13:1177-85. [CENTRAL: PMC4284947] [DOI: 10.1016/S1474-4422(14)70224-8]SharmaM , PearceLA , BenaventeOR , AndersonDC , ConnollySJ , PalacioS , et al. Predictors of mortality in patients with lacunar stroke in the Secondary Prevention of Small Subcortical Strokes trial. Stroke; a Journal of Cerebral Circulation2014;45(10):2989–94. [CENTRAL: PMC4175186] [DOI: doi.org/10.1161/STROKEAHA.114.005789] [PMID: 25158772]The SPS3 Investigators, BenaventeOR , CoffeyCS , ConwitR , HartRG , McClureLA , PearceLA , et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. New England Journal of Medicine2012;367(9):817-25. [DOI: 10.1056/NEJMoa1204133]">Pearce SPS3 2014</a> was a stroke secondary prevention trial and cognition was a secondary aim. Arguably <a href="./references#CD012269-bbs2-0001" title="JiaJ , WeiC , LiangJ , ZhouA , ZuoX , SongH , et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischaemic small vessel disease: a multicentre, randomised, double-blind, placebo-controlled trial. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2016;12(2):89-99. [DOI: 10.1016/j.jalz.2015.04.010] [PMID: 26086183]">Jia 2016</a> was the study closest to our original aim in terms of population and outcomes assessed, but the medication studied was not primarily tested as an antithrombotic therapy, although it does possess antithrombotic properties. Moreover, this study had relatively restricted age range (50 to 70 years), making it difficult to generalise these findings to the general population. Both <a href="./references#CD012269-bbs2-0001" title="JiaJ , WeiC , LiangJ , ZhouA , ZuoX , SongH , et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischaemic small vessel disease: a multicentre, randomised, double-blind, placebo-controlled trial. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2016;12(2):89-99. [DOI: 10.1016/j.jalz.2015.04.010] [PMID: 26086183]">Jia 2016</a> and <a href="./references#CD012269-bbs2-0002" title="MaestriniI , AltieriM , ClementeLD , VicenziniE , PantanoP , RazE , et al. Longitudinal study on low-dose aspirin versus placebo administration in silent brain infarcts: the SILENCE study. Stroke Research and Treatment2018;2018(7532403):1-9. [DOI: doi.org/10.1155/2018/7532403]">Maestrini SILENCE 2018</a> had a small sample size and relatively short follow‐up for a cognitive prevention study, and this is reflected in the uncertainty around their results. Even the largest trial may not have been adequately powered for some of our efficacy and safety outcomes, for example, incident MCI and intracerebral bleeding (<a href="./references#CD012269-bbs2-0003" title="PearceLA , McClureLA , AndersonDC , JacovaC , SharmaM , HartRG , et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurology2014;13:1177-85. [CENTRAL: PMC4284947] [DOI: 10.1016/S1474-4422(14)70224-8]SharmaM , PearceLA , BenaventeOR , AndersonDC , ConnollySJ , PalacioS , et al. Predictors of mortality in patients with lacunar stroke in the Secondary Prevention of Small Subcortical Strokes trial. Stroke; a Journal of Cerebral Circulation2014;45(10):2989–94. [CENTRAL: PMC4175186] [DOI: doi.org/10.1161/STROKEAHA.114.005789] [PMID: 25158772]The SPS3 Investigators, BenaventeOR , CoffeyCS , ConwitR , HartRG , McClureLA , PearceLA , et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. New England Journal of Medicine2012;367(9):817-25. [DOI: 10.1056/NEJMoa1204133]">Pearce SPS3 2014</a>).  </p> </section> <section id="CD012269-sec-0069"> <h3 class="title" id="CD012269-sec-0069">Potential biases in the review process</h3> <p>To keep our review focussed, we operationalised our definitions of cSVD. This may have excluded some studies with potentially relevant data. The data did not allow for an assessment of publication bias. See <a href="#CD012269-fig-0002">Figure 2</a> and <a href="#CD012269-fig-0003">Figure 3</a> for full details. </p> </section> <section id="CD012269-sec-0070"> <h3 class="title" id="CD012269-sec-0070">Agreements and disagreements with other studies or reviews</h3> <section id="CD012269-sec-0071"> <h4 class="title">Agreements with guidelines </h4> <p>The recently published European Stroke Organisation (ESO) guideline on covert cSVD gave a weak recommendation against using antithrombotic therapy such as aspirin for cognitive decline, but recognised that the quality of supporting evidence was weak (<a href="./references#CD012269-bbs2-0063" title="WardlawJM , DebetteS , JokinenH , De LeeuwFE , PantoniL , ChabriatH , et al. ESO Guideline on covert cerebral small vessel disease. European Stroke Journal2021;6(2):111-62. [DOI: 10.1177/23969873211012132]">Wardlaw 2021</a>). However, the ESO guideline did recommend people with covert cSVD and hypertension to have their blood pressure well controlled, and it emphasised that RCTs with specific clinical endpoints were a priority for covert cSVD. An accompanying expert consensus statement noted that antiplatelets should not be used unless there is another clinical indication as these drugs may be harmful, especially in older adults. While this guideline considered randomised and non‐randomised evidence and had a broader definition of cSVD, the conclusions are aligned with the findings of our review. </p> <p>The Geriatric Neurology Group of the Chinese Society of Geriatrics published a clinical practice guideline on cognitive impairment in cSVD (<a href="./references#CD012269-bbs2-0054" title="PengD . Clinical practice guideline for cognitive impairment of cerebral small vessel disease. Aging Medicine (Milton)2019;2:64-73. [DOI: 10.1002/agm2.12073]">Peng 2019</a>). This guideline referred to <a href="./references#CD012269-bbs2-0003" title="PearceLA , McClureLA , AndersonDC , JacovaC , SharmaM , HartRG , et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurology2014;13:1177-85. [CENTRAL: PMC4284947] [DOI: 10.1016/S1474-4422(14)70224-8]SharmaM , PearceLA , BenaventeOR , AndersonDC , ConnollySJ , PalacioS , et al. Predictors of mortality in patients with lacunar stroke in the Secondary Prevention of Small Subcortical Strokes trial. Stroke; a Journal of Cerebral Circulation2014;45(10):2989–94. [CENTRAL: PMC4175186] [DOI: doi.org/10.1161/STROKEAHA.114.005789] [PMID: 25158772]The SPS3 Investigators, BenaventeOR , CoffeyCS , ConwitR , HartRG , McClureLA , PearceLA , et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. New England Journal of Medicine2012;367(9):817-25. [DOI: 10.1056/NEJMoa1204133]">Pearce SPS3 2014</a>, but did not make any recommendations on antithrombotic therapy; it recognised that the evidence around pharmacological treatment of vascular risk factors for cSVD was weak. </p> <p>The American Heart Association/American Stroke Association published guidelines on prevention of stroke in people with silent cerebrovascular disease. Their neuroimaging definition of silent cerebrovascular disease is similar to our review definition of cSVD. No formal recommendations were made around antithrombotic therapy due to the lack of suitable trials (<a href="./references#CD012269-bbs2-0060" title="SmithEE , SaposnikG , BiesselsGJ , DoubalFN , FornageM , GorelickPB , et al, American Heart Association Stroke Council, Council on Cardiovascular Radiology and Intervention, Council on Functional Genomics and Translational Biology, and Council on Hypertension. Prevention of stroke in patients with silent cerebrovascular disease: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke2017;48(6):e44-e71. [DOI: doi.org/10.1161/STR.0000000000000116]">Smith 2017</a>).  </p> </section> <section id="CD012269-sec-0072"> <h4 class="title">Agreements with other studies </h4> <p>While we strived to ensure that we included all studies relevant to our review question, there were other studies that offered insights into antithrombotic therapy and vascular cognitive decline. The ASPREE (Aspirin in Reducing Events in the Elderly) study described the use of aspirin to prevent cardiovascular events, and physical and cognitive decline in older adults (<a href="./references#CD012269-bbs2-0048" title="McNeilJJ , WoodsRL , NelsonMR , ReidCM , KirpachB , WolfeR , et al. Effect of aspirin on disability-free survival in the healthy elderly. New England Journal of Medicine2018;379:1499-508. [DOI: 10.1056/NEJMoa1800722]">McNeil 2018</a>). Although baseline neuroimaging was not mandated in this study, it is possible that a proportion of the participants might have had a degree of cSVD changes. The primary results of ASPREE are aligned with the summary findings in this review, and aspirin did not appear to have any apparent benefit on cognitive or physical function, but was associated with increased harm. </p> <p>There are studies that describe the effect of antithrombotic therapy on the progression of neuroradiological markers of cSVD. We found two trials of an antiplatelet agent, cilostazol. In one RCT, 89 participants with type II diabetes mellitus and no brain lesions on baseline MRI scans were randomised to cilostazol or placebo, and followed up for three years  (<a href="./references#CD012269-bbs2-0059" title="Shinoda-TagawaT , YamasakiY , YoshidaS , KajimotoY , TsujinoT , HakuiN , et al. A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with Type II diabetes. Diabetologia2002;45:188-94. [DOI: 10.1007/s00125-001-0740-2]">Shinoda‐Tagawa 2002</a>). The study found fewer silent infarcts in the cilostazol group. The LACI‐1 (LACunar Intervention‐1) RCT of 57 participants with recent lacunar stroke reported that 11 weeks of cilostazol reduced progression in white matter lesions compared to placebo (<a href="./references#CD012269-bbs2-0030" title="BlairGW , AppletonJP , FlahertyK , DoubalF , SpriggN , DooleyR , et al. Tolerability, safety and intermediary pharmacological effects of cilostazol and isosorbide mononitrate, alone and combined, in patients with lacunar ischaemic stroke: the LACunar Intervention-1 (LACI-1) trial, a randomised clinical trial. EClinicalMedicine2019;11:34-43. [DOI: 10.1016/j.eclinm.2019.04.001]">Blair 2019</a>). While these data are interesting, the relationship between neuroimaging features of cSVD and clinical manifestations was unclear and so for our review, we did not include studies that only reported surrogate measures such as silent brain infarction. </p> <p>Although we were unable to obtain individual participant data or subgroup data limited to cSVD, studies of antithrombotic therapy for stroke can still give some relevant information. The Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial showed no significant differences in cognitive outcomes between two antiplatelet regimens (aspirin plus extended‐release dipyridamole versus clopidogrel) (<a href="./references#CD012269-bbs2-0035" title="DienerHC , SaccoRL , YusufS , CottonD , OunpuuS , LawtonWA , et al. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurology2008;7:875-84. [DOI: 10.1016/S1474-4422(08)70198-4]">Diener 2008</a>). The agent DL‐3‐n‐butylphthalide has also been studied in acute ischaemic stroke, where there was no difference in cognitive test scores. However, the sample size was small for a cognitive study (104 participants) and follow‐up was only for one month (<a href="http://yan%202017/" target="_blank">Yan 2017</a>).  </p> </section> <section id="CD012269-sec-0073"> <h4 class="title">Agreement with other reviews </h4> <p>In a systematic review and meta‐analysis looking at antithrombotic therapy following lacunar stroke (a form of cSVD), the authors described benefit of single antiplatelet versus placebo for prevention of recurrent stroke. However, there was no signal of superiority of one antithrombotic agent over another, and long‐term dual antiplatelet was associated with harm. The review did not examine cognitive outcomes (Kwok 2015).  </p> <p>One Cochrane Review describing aspirin for prevention of cognitive decline found few studies, but noted no clear signal of benefit and the potential for harmful adverse effects (<a href="./references#CD012269-bbs2-0045" title="JordanF , QuinnTJ , McGuinnessB , PassmoreP , KellyJP , Tudur SmithC , et al. Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. Cochrane Database of Systematic Reviews2020, Issue 4. Art. No: CD011459. [DOI: 10.1002/14651858.CD011459.pub2]">Jordan 2020</a>). </p> <p>We found no primary studies or reviews examining oral anticoagulants in our population of interest. In one systematic review that examined the relationship between atrial fibrillation thromboprophylaxis and cognitive decline (<a href="./references#CD012269-bbs2-0050" title="MoffittP , LaneDA , ParkH , O'ConnellJ , QuinnTJ . Thromboprophylaxis in atrial fibrillation and association with cognitive decline: systematic review. Age Ageing2016;45(6):767-75. [DOI: doi.org/10.1093/ageing/afw104]">Moffitt 2016</a>), the authors found no definitive evidence of cognitive benefit or harm from anticoagulation over antiplatelet therapy. Since the publication of this review, one large observational cohort study of 3284 older (over 65 years) Chinese people with AF followed up for 3.6 years found that anticoagulation with warfarin was associated with a significantly lower risk of new‐onset dementia compared those with no therapy or aspirin, with an HR of 0.14 (95% CI 0.05 to 0.36; P &lt; 0.001) (<a href="./references#CD012269-bbs2-0065" title="WongCK , HuangD , ZhouM , HaiJ , YueWS , LiWH , et al. Antithrombotic therapy and the risk of new-onset dementia in elderly patients with atrial fibrillation. Postgraduate Medicine Journal2020;12:1-6. [DOI: 10.1136/postgradmedj-2020-137916]">Wong 2020</a>). Interestingly, in this study, people receiving warfarin with time in therapeutic range (TTR) of greater than 65% had a non‐significant trend towards a lower risk of dementia compared with those with TTR less than 65% (<a href="./references#CD012269-bbs2-0065" title="WongCK , HuangD , ZhouM , HaiJ , YueWS , LiWH , et al. Antithrombotic therapy and the risk of new-onset dementia in elderly patients with atrial fibrillation. Postgraduate Medicine Journal2020;12:1-6. [DOI: 10.1136/postgradmedj-2020-137916]">Wong 2020</a>). </p> <p>In one narrative review of cSVD, <a href="./references#CD012269-bbs2-0051" title="MokV , KimJS . Prevention and management of cerebral small vessel disease. Journal of Stroke2015;17:111-22. [DOI: 10.5853/jos.2015.17.2.111]">Mok 2015</a> noted the substantial risk of bleeding when antithrombotics were used. Given the theoretical reduced bleeding risk with certain antithrombotic classes, a recommendation was made to consider using cilostazol or triflusal (over aspirin) in people living with cSVD.  </p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012269-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012269.pub2/media/CDSR/CD012269/urn:x-wiley:14651858:media:CD012269:CD012269-FIG-01" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD012269-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012269.pub2/media/CDSR/CD012269/image_n/nCD012269-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012269.pub2/media/CDSR/CD012269/image_t/tCD012269-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012269.pub2/full#CD012269-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012269.pub2/media/CDSR/CD012269/image_n/nCD012269-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012269-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012269.pub2/media/CDSR/CD012269/urn:x-wiley:14651858:media:CD012269:CD012269-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012269-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012269.pub2/media/CDSR/CD012269/image_n/nCD012269-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012269.pub2/media/CDSR/CD012269/image_t/tCD012269-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012269.pub2/full#CD012269-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012269.pub2/media/CDSR/CD012269/image_n/nCD012269-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012269-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012269.pub2/media/CDSR/CD012269/urn:x-wiley:14651858:media:CD012269:CD012269-FIG-03" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD012269-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012269.pub2/media/CDSR/CD012269/image_n/nCD012269-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012269.pub2/media/CDSR/CD012269/image_t/tCD012269-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012269.pub2/full#CD012269-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012269.pub2/media/CDSR/CD012269/image_n/nCD012269-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012269-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antiplatelet drug compared to placebo in mixed populations (with or without pre‐existing antiplatelet therapy) for the prevention of cognitive decline and dementia in people with cerebral small vessel disease and no dementia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Antiplatelet drug compared to placebo, in populations with mixed prevalence of antiplatelet drug use at baseline, for the prevention of cognitive decline and dementia in people with cerebral small vessel disease and no dementia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with cerebral small vessel disease and no dementia either already on antiplatelet therapy or not<br/><b>Setting:</b> outpatient services<br/><b>Intervention:</b> adding antiplatelet therapy in populations where some participants may have been taking antiplatelet <br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Impact</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in cognitive function from baseline</b><br/>assessed with ADAS‐Cog, CIBIC‐plus, MMSE, CDR, CDR‐SB,  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 trial reported a beneficial effect across 2 of 5 cognitive outcomes (ADAS‐Cog and CIBIC‐plus), but the size of benefit may be less than the minimal important clinical difference. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incident dementia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major bleeding (intracranial and extracranial)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 trial reported no difference between treatment groups for this outcome.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Functional ability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 trial reported no difference in functional anility between treatment groups</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stroke or transient ischaemic attack</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 trial reported no difference in stroke or transient ischaemic attacks between treatment groups </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any adverse events (excluding major bleeding)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 study reported no difference in adverse events between treatment groups</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal from study medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 trial reported an increase in medication withdrawal in those taking additional antiplatelets in comparison to those taking a placebo (OR for withdrawal from treatment 1.88, 95% CI 0.90 to 3.42) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ADAS‐Cog:</b> Alzheimer's Disease Assessment Scale – Cognitive Subscale; <b>ADL:</b> activities of daily living; <b>CDR‐SB:</b> Clinical Dementia Rating scale Sum of Boxes;<b> CI:</b> confidence interval; <b>MMSE:</b> Mini‐Mental State Examination; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level because all participants had cognitive impairment at baseline, making it difficult to translate these findings to the general small‐vessel disease population.<br/><sup>b</sup>Downgraded one level as it is arguable whether DL‐3‐n‐butylphthalide should technically be classified as an antithrombotic therapy.<br/><sup>c</sup>Downgraded one level for imprecision as only one study contributed to this finding. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antiplatelet drug compared to placebo in mixed populations (with or without pre‐existing antiplatelet therapy) for the prevention of cognitive decline and dementia in people with cerebral small vessel disease and no dementia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012269.pub2/full#CD012269-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012269-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Antiplatelet therapy compared to placebo for prevention of cognitive decline and dementia in people with cerebral small vessel disease and no dementia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Antiplatelet therapy compared to placebo in antiplatelet naive populations for prevention of cognitive decline and dementia in people with cerebral small vessel disease and no dementia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with cerebral small vessel disease and no dementia not on antiplatelet therapy<br/><b>Setting: </b> outpatient services<br/><b>Intervention:</b> antiplatelet therapy<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Impact</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in cognitive function from baseline</b><br/>assessed with: NPB,  MMSE </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 trial reported no difference between treatment groups.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incident dementia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major bleeding (intracranial and extracranial)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Functional ability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 trial reported no difference in activities of daily living between treatment groups.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stroke or transient ischaemic attack</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 trial reported no difference between treatment groups.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any adverse events (excluding major bleeding)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 trial reported no difference between treatment groups.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal from study medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 trial reported slightly more dropout in the intervention group (33.3%) than in the placebo group (19.2%) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>MMSE:</b> Mini‐Mental State Examination; <b>NPB:</b> Neuropsychological test Battery; <b>RCT:</b> randomised controlled trial.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level as there was no (clear) statement whether participants with dementia were actively excluded.<br/><sup>b</sup>Downgraded one level due to serious risk of bias in included studies.<br/><sup>c</sup>Downgraded one level due to imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Antiplatelet therapy compared to placebo for prevention of cognitive decline and dementia in people with cerebral small vessel disease and no dementia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012269.pub2/full#CD012269-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012269-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Dual antiplatelet therapy compared to single antiplatelet therapy for prevention of cognitive decline and dementia in people with cerebral small vessel disease and no dementia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Dual antiplatelet therapy compared to single antiplatelet therapy for prevention of cognitive decline and dementia in people with cerebral small vessel disease and no dementia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with cerebral small vessel disease and no dementia<br/><b>Setting:</b> outpatient services<br/><b>Intervention:</b> dual antiplatelet therapy<br/><b>Comparison:</b> single antiplatelet therapy </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Impact</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in cognitive function from baseline</b><br/>assessed with CASI score </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 trial reported no beneficial effect of additional antiplatelet treatment over placebo on cognitive functioning assessed with the CASI score. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3020<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incident dementia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No trials reported this outcome</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major bleeding (intracranial and extracranial)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 trial reported a difference in major haemorrhagic events (105/1517 participants with intervention vs 56/1503 participants with control; HR 1.97, 95% CI 1.41 to 2.71) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3020<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Functional ability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No trials reported this outcome.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stroke or transient ischaemic attack</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 trial reported there was probably no effect of additional antiplatelet treatment on stroke or TIA </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3020<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any adverse events (excluding major bleeding)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No trials reported this outcome.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal from study medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 trial reported an increase in medication withdrawal in those taking additional antiplatelets in comparison to those taking a placebo (30% with intervention vs 27% with control; P = 0.02). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3020<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CASI:</b> Cognitive Abilities Screening Instrument; <b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>RCT:</b> randomised controlled trial.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for imprecision as only one study contributed to this finding.<br/><sup>b</sup>Downgraded one level for indirectness because most participants had mild cognitive impairment at baseline, making it difficult to translate these findings to the general small‐vessel disease population. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Dual antiplatelet therapy compared to single antiplatelet therapy for prevention of cognitive decline and dementia in people with cerebral small vessel disease and no dementia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012269.pub2/full#CD012269-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012269-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Results of Jia 2016 (efficacy outcomes in intention‐to‐treat population at week 24)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Psychometric scores</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Adjusted mean change from baseline</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Difference in adjusted mean (95% CI)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>DL‐3‐n‐butylphthalide</b> </p> <p><b>(n = 140)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> <p><b>(n = 140)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADAS‐Cog</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−2.46 (SE 0.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.39 (SE 0.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.07 (−2.02 to −0.12)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CIBIC‐plus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.24 (SE 0.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.53 (SE 0.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.29 (−0.48 to −0.10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MMSE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.51 (SE 0.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.26 (SE 0.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26 (−0.25 to 0.76)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.05 (SE 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.02 (SE 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.02 (−0.06 to 0.02)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDR‐SB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.03 (SE 0.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.07 (SE 0.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.04 (−0.16 to 0.24)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.62 (SE 0.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.80 (SE 0.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.18 (−0.70 to 1.07)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.13 (SE 0.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.43 (SE 0.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.29 (−0.15 to 0.74)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>Results table extracted from Table 2, <a href="./references#CD012269-bbs2-0001" title="JiaJ , WeiC , LiangJ , ZhouA , ZuoX , SongH , et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischaemic small vessel disease: a multicentre, randomised, double-blind, placebo-controlled trial. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2016;12(2):89-99. [DOI: 10.1016/j.jalz.2015.04.010] [PMID: 26086183]">Jia 2016</a>. The adjustments made to the mean were not clearly stated in the publication.<br/>ADAS‐Cog: 12‐item Alzheimer's Disease Assessment Scale‐Cognitive subscale; ADL: activities of daily living; CDR: Clinical Dementia Rating; CDR‐SB: Clinical Dementia Rating scale Sum of Boxes; CI: confidence interval; CIBIC‐plus: Clinician's Interview‐Based Impression of Change‐Plus Caregiver Input; MMSE: Mini‐Mental State Examination; n: number of participants; NPI: Neuropsychiatric Inventory; SE: standard error. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Results of Jia 2016 (efficacy outcomes in intention‐to‐treat population at week 24)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012269.pub2/full#CD012269-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012269-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Results of SPS3 2014 (mean Cognitive Abilities Screening Instrument (CASI) z‐score over time by assigned antiplatelet treatment)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Time since baseline assessment (years)</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Aspirin + clopidogrel</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Aspirin + placebo</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SD</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1468</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.48</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>974</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>769</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>411</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.60</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>Results table extracted from <a href="./references#CD012269-bbs2-0003" title="PearceLA , McClureLA , AndersonDC , JacovaC , SharmaM , HartRG , et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurology2014;13:1177-85. [CENTRAL: PMC4284947] [DOI: 10.1016/S1474-4422(14)70224-8]SharmaM , PearceLA , BenaventeOR , AndersonDC , ConnollySJ , PalacioS , et al. Predictors of mortality in patients with lacunar stroke in the Secondary Prevention of Small Subcortical Strokes trial. Stroke; a Journal of Cerebral Circulation2014;45(10):2989–94. [CENTRAL: PMC4175186] [DOI: doi.org/10.1161/STROKEAHA.114.005789] [PMID: 25158772]The SPS3 Investigators, BenaventeOR , CoffeyCS , ConwitR , HartRG , McClureLA , PearceLA , et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. New England Journal of Medicine2012;367(9):817-25. [DOI: 10.1056/NEJMoa1204133]">Pearce SPS3 2014</a>. Higher score indicates better performance.<br/>n: number of participants; SD: standard deviation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Results of SPS3 2014 (mean Cognitive Abilities Screening Instrument (CASI) z‐score over time by assigned antiplatelet treatment)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012269.pub2/full#CD012269-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012269-tbl-0006"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Results of SILENCE 2018 (efficacy outcomes of the  randomised participants)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Aspirin</b> </p> <p><b>(n = 24)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> <p><b>(n = 26)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MMSE (median) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29 (IQR 27–30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29 (IQR 27–30) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IADL (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (IQR 8–8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> 8 (IQR 8–8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADL (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (IQR 6–6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (IQR 6–6) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loss to follow‐up (n) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> 8 (33.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (19.2%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events (n)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (8.3%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> 1 (3.8%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in global cognitive score (mean) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.10 (SD 0.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.06 (SD 0.55)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>Unpublished data provided by the authors of <a href="./references#CD012269-bbs2-0002" title="MaestriniI , AltieriM , ClementeLD , VicenziniE , PantanoP , RazE , et al. Longitudinal study on low-dose aspirin versus placebo administration in silent brain infarcts: the SILENCE study. Stroke Research and Treatment2018;2018(7532403):1-9. [DOI: doi.org/10.1155/2018/7532403]">Maestrini SILENCE 2018</a>.<br/>ADL: activities of daily living; IADL: Instrumental Activities of Daily Living; IQR: interquartile range; MMSE: Mini‐Mental State Examination; n: number of participants; SD: standard deviation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Results of SILENCE 2018 (efficacy outcomes of the  randomised participants)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012269.pub2/full#CD012269-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012269.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012269-note-0011">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012269-note-0018">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012269-note-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012269-note-0017">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD012269-note-0014">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD012269-note-0013">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD012269-note-0016">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012269-note-0012">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012269\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012269\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012269\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012269\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012269\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012269\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012269\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012269\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012269\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012269\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012269\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012269\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012269\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012269\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012269\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012269\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012269\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012269\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=BqmVIxTs&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012269.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012269.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012269.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012269.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012269.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725218513"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012269.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725218517"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012269.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e75e09bd51be5',t:'MTc0MDcyNTIxOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 